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Abstract 
 
Staphylococcus aureus is a remarkably pathogenic bacterium that is widely prevalent 
among the human population. It is the leading agent of skin and soft tissue infections, 
and is also responsible for causing an array of severe and life threatening diseases. The 
invasiveness of the pathogen, coupled with increasing antibiotic resistance seen for S. 
aureus infections, makes this bacterium a prominent public health concern. The 
extended pathogenicity of S. aureus is largely due to its repertoire of virulence factors, 
which are typically characterized by being bound to the cell wall, or secreted into the 
extracellular environment. Previously, our lab identified a leucine aminopeptidase 
mutant (pepZ) as being strongly attenuated in virulence for both systemic and localized 
models of infection. Importantly, PepZ marked the first intracellular bacterial 
aminopeptidase found to be involved in pathogenesis in Gram-positive bacteria. In this 
study, we set out to explore the role of the remaining eleven, non-essential, 
uncharacterized aminopeptidase enzymes in S. aureus disease causation, and present 
two additional aminopeptidase genes, pepT1 and pepT2, which are important for 
virulence in both human ex vivo models, and murine in vivo models of disease. 
Interestingly, these enzymes do not appear to be necessary for the utilization of free 
peptides for cellular nutrition and metabolism, which is a typical characteristic of 
aminopeptidases. Transcriptional analysis reveals maximal expression of pepT1 and 
pepT2 during early exponential growth phase, while localization mapping demonstrates 
viii 
that the PepT1 and PepT2 enzymes are found in the bacterial cytoplasm during all 
stages of growth. To explore these findings on a global level, an in-depth proteomic 
investigation of cleavage properties and cellular substrates identified several proteins as 
having significant changes in N-terminal peptide abundance in pepT1 and pepT2 
mutant proteomes. We identified a number of putative independent and shared targets 
for the PepT1 and PepT2 enzymes that are known to impact cellular fitness and 
pathogenesis, including: DnaK, a heat shock protein conserved throughout all 
organisms, which functions to help deal with mis-folded and aggregated proteins that 
have accumulated as a result of cellular stress; ArlR, the response regulator of the 
ArlRS two-component system, which is an important regulator of agglutination and 
virulence in S. aureus; and of special interest, ClpC, an ATP-dependent protease 
chaperone which is a component of the primary machinery by which protein degradation 
occurs in S. aureus. Collectively, our data proves the importance of the PepT 
aminopeptidase enzymes in S. aureus pathogenesis, and indicates these enzymes are 
likely involved in bacterial stress response and virulence by functioning through the 
bioactivation/inactivation of key cellular proteins.  
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Introduction 
 
Staphylococcus aureus. Staphylococcus aureus is a Gram-positive opportunistic 
pathogen, which was first discovered in 1880 in the pus secretions from a knee joint 
abscess, by the surgeon Alexander Ogston (1). The bacterium is found to colonize the 
skin, anterior nares, and upper respiratory tract of humans and also a wide range of 
animals (2-4). It is a non-spore forming member of the Firmicutes, a phyla consisting of 
bacteria characterized by a low G+C chromosomal content. S. aureus gets its name 
from the yellow-gold colored, cocci shape of its cells, which arrange together to form 
grape-like clusters (5, 6). The notable golden pigment of the bacterium is a result of the 
membrane-bound carotenoid staphyloxanthin, which is involved in enhancing the 
virulence and fitness of the cell by protecting against exogenous stressors and DNA 
damage (7, 8). S. aureus is further characterized by being a catalase-positive, 
facultative anaerobe, which is capable of complete hemolysis of red blood cells, as well 
as surviving significantly hostile environmental conditions (9, 10). Additional analysis of 
S. aureus indicates it has a genome size of approximately 2.81Mb, which has a 32.8% 
G+C chromosomal content, and contains plasmids, prophages, and multiple 
pathogenicity islands (11-13).  
 
Disease Causation of S. aureus. Although there are more than 40 species of 
Staphylococcus, Staphylococcus aureus stands alone in its severe disease causation in 
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humans. S. aureus is highly prevalent among humans, commensally and 
asymptomatically colonizing approximately 20-40% of the adult population (14). Even in 
its commensal state, carriers of S. aureus have an increased propensity of developing 
an infection, and are key reservoirs for spread of the bacterium amongst individuals. 
Unsurprisingly, the most prominent mode of transmission of S. aureus is through 
human-human contact via commensally colonized individuals, while direct contact with 
contaminated surfaces is likely to play a much smaller, although nonetheless important, 
role in transmission (15, 16). The bacterium’s preferred niche consists of the skin and 
mucous membranes of humans, and, despite being an effective barrier against bacterial 
invasion, even minor skin damage or mucosal trauma can easily allow S. aureus to gain 
access to underlying tissues or the bloodstream; and cause infections (17). Once inside 
the body, it begins to invade host tissues and form a biofilm through attachment to host 
extracellular matrix proteins (18). In addition, S. aureus will utilize the bloodstream to 
spread to other organs in the host. Although the bloodstream is a notably harsh 
environment for bacterial survival due to an abundance of host immune factors, it has 
been proposed that S. aureus may actually exploit these factors as a mode of 
dissemination. A recent study shows that S. aureus has the ability to survive and 
proliferate inside professional phagocytes for several days without affecting viability, 
until the bacterium lyses the cell and escapes (19). Thus, S. aureus potentially utilizes 
these “mobile cells” as a vessel for dissemination of infection.  
 
Due to the frequent colonization of humans, and the pathogens ease of invasion, S. 
aureus is the leading cause of skin and soft tissue infections (20, 21), which include 
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abscesses, consisting of pockets of infection which form at the site of injury, impetigo, 
which causes pustules and skin sores, and cellulitis, an infection of the underlying 
layers of the skin (20, 22). S. aureus is also responsible for causing a plethora of severe 
diseases, such as endocarditis, an infection of the inner layer of the heart, toxic shock 
syndrome resulting from exposure to large amounts of bacterial toxin, pneumonia, and 
osteomyelitis (23). Colonization of medical devices and catheters is also common with 
S. aureus infections, and is a result of its ability to form a biofilm within the host (24). In 
addition, several host related factors such as immunodeficiency, neutrophil defects, and 
the presence of underlying diseases result in a particularly high risk of S. aureus 
infection due to a diminished immune response to the pathogen (25).   
 
S. aureus Antibiotic Resistance. Prior to the discovery and deployment of antibiotics, 
Staphylococcus aureus related bacteremia had mortality rates of approximately 80% 
(26). However, even in the current “antibiotic era”, S. aureus infection is a mounting 
concern due to the increasing difficulty in treatment as a result of the pathogens 
notorious antibiotic resistance (27, 28). It should be noted that S. aureus is naturally 
susceptible to essentially every antibiotic thus far developed, however, resistance is 
frequently acquired through horizontal gene transfer, and chromosomal mutation (25). It 
was this remarkable antibiotic susceptibility that originally led to the unearthing of the 
“wonder drug” penicillin, and it’s application in clinical practice in the 1940’s. However, 
less than two years after the introduction of penicillin, S. aureus strains were already 
acquiring resistance, and the pathogen had once again become a major problem in 
hospital and healthcare settings (22). Within a decade, penicillin resistant S. aureus 
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strains had disseminated from hospitals and into the community. It was estimated that 
more than 80% of all hospital and community acquired S. aureus isolates were resistant 
to penicillin only 20 years after the introduction of the drug (29). Penicillin resistance in 
S. aureus is mediated by blaZ, which is a gene encoding β-lactamase (30, 31). When 
exposed to penicillin, the bacterium synthesizes β-lactamase, which then renders the 
antibiotic inactive by hydrolyzing the β-lactam ring (29, 31).  
 
In 1961, methicillin, a semi-synthetic β-lactamase-resistant penicillin, was introduced to 
combat the ever-increasing burden of drug resistance seen with S. aureus infections 
(32, 33). The battle was short lived, however, with the rapid emergence of methicillin 
resistant S. aureus clones. Methicillin resistance in S. aureus is characterized by a 
chromosomal gene, mecA, which encodes a penicillin-binding protein, PBP 2’ (34). PBP 
2’ is a membrane-bound protein which shares similar function to serine proteases, and 
is responsible for catalyzing the transpeptidation reaction necessary for cross-linking 
peptidoglycan chains in the cell membrane (35). The PBP 2’ enzyme is unique in that it 
confers resistance to all β-lactam antibiotics, including the cephalosporins, by blocking 
antibiotic access to the active site of the enzyme, while still allowing the transpeptidation 
reaction to continue (36). The mecA gene is located on a sizeable mobile genetic 
element, designated the staphylococcal cassette chromosome SCCmec (37, 38). 
Acquisition of SCCmec occurs through lateral gene transfer, however the genetic 
mechanisms responsible for this are still largely unknown. S. aureus strains which have 
acquired the chromosomally localized mecA gene, and thus have resistance to β-lactam 
antibiotics, including the penicillins and the cephalosproins, are termed methicillin-
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resistant Staphylococcus aureus (MRSA) strains.  In contrast, S. aureus strains lacking 
the mecA gene, which are thus sensitive to these antibiotics, are termed methicillin-
sensitive Staphylococcus aureus (MSSA) strains (39). This broad resistance of MRSA 
strains to the entire class of beta-lactams is unlike the previously described 
penicillinase-mediated resistance, which is very narrow in spectrum (25). 
 
With the mounting staphylococcal resistance to methicillin, glycopeptide antibiotics, 
including vancomycin, are often the treatment of choice for severe infections caused by 
MRSA (40). Vancomycin was originally approved by the US Food and Drug 
Administration in 1958; nearly the same time as the introduction of methicillin (41). 
However, due to the perceived toxicity and questionable efficacy, vancomycin was only 
administered to patients with severe β-lactam allergies, or as a last resort for those who 
showed infections resistant to antibiotics previously implemented (42). It wasn’t until the 
1980s that the continued appearance of MRSA strains prompted the resurgence of 
vancomycin use, due to its characteristic activity against such isolates. The antibiotic 
works through a different mechanism than β-lactam antibiotics, and blocks proper cell 
wall synthesis and NAM/NAG crosslinking by binding to the terminal D-Ala-D-Ala 
moieties of the NAM/NAG peptides, which form the backbone of the cell wall (43). Since 
the widespread administration of vancomycin, strains of S. aureus have emerged that 
differ in susceptibility to the drug. A vancomycin-intermediate S. aureus (VISA) strain, 
characterized by reduced susceptibility to vancomycin, was first reported in Japan in 
1997, from the surgical would of an infant (44). The reduced susceptibility evolved due 
to selective pressures, and can be attributed to the over prescription of vancomycin to 
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treat MRSA infections. Studies have since shown that consecutive point mutations 
within central global regulatory genes contribute to the VISA phenotype, which is 
predominantly associated with the restructuring of cell wall metabolism (41, 45). These 
vancomycin-insensitive strains have a larger amount of synthesized peptidoglycan, 
causing the cells to have thicker, irregularly shaped cell walls (46). In addition, there is a 
significant decrease in the amount of cross-linking, which exposes D-Ala-D-Ala 
residues, causing vancomycin to bind and thus become trapped in the cell wall (29). Not 
only does this result in vancomycin insensitivity, but also mediates resistance to other 
antibiotics by impairing their ability to reach the cell membrane. The first S. aureus 
clinical isolate with high-level, or “true resistance”, to vancomycin (VRSA) was reported 
in 2002, in Michigan (47). VRSA strains have acquired the vanA operon, which is 
conjugally transferred from Enterococcus species, and permits synthesis of D-Ala-D-Lac 
instead of D-Ala-D-Ala (48). The resulting dipeptide has a markedly reduced affinity for 
vancomycin, and allows cell wall peptidoglycan assembly to continue. Although only a 
few VRSA cases have been reported thus far, the increasing drug resistance seen for 
S. aureus infections, coupled with a limited availability of novel treatment methods, 
makes this organism a severe concern, and fosters an extreme need for a better 
understanding of its pathogenesis.  
 
Hospital and Community Acquired MRSA. Originally, MRSA infections were limited 
to acquisition in a hospital or health care environment, largely affecting elderly, 
debilitated adults and were thus termed Hospital-associated MRSA (HA-MRSA) (49). It 
wasn’t until 1981 that the first Community-associated MRSA (CA-MRSA) infection was 
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reported in intravenous drug users in Detroit, shortly followed by 4 CA-MRSA deaths of 
children in Minnesota and North Dakota in 1997 (50, 51). Subsequently, in the late 
1990s, other healthy community populations were reported as acquiring MRSA 
infections, even those with no previous hospital exposure or outlying predisposition for 
the acquisition of MRSA (52). Previously, the term ‘MRSA’ simultaneously implied HA-
MRSA, however, after the emergence of CA-MRSA infections, the Centers for Disease 
Control and Prevention (CDC) outlined a criteria to differentiate between HA-MRSA and 
CA-MRSA (49). This differentiation was necessary because the epidemiology, clinical 
appearance, and microbiologic characteristics of CA-MRSA strains differ substantially 
from those associated with hospital settings (21, 52).  
 
CA-MRSA isolates are characterized by increased virulence, and are normally isolated 
from patients whom are otherwise healthy individuals (53). Two CA-MRSA clones, 
USA300 and USA400, are responsible for the majority of infections; however recently, 
USA300 has become the more prevalent isolate (20, 54-56). USA300 is distinct from 
other MRSA strains, and is of serious concern due to the severe invasive infections the 
strain causes, such as bacteremia, endocarditis, fatal brain abscesses, severe 
respiratory infections, joint infections, and complicated skin infections (57-60). In 
addition, USA300 is also being increasingly reported as invading hospitals and 
healthcare settings and becoming a cause of many HA-MRSA-type infections (53, 61, 
62). USA300 also appears to be more easily transmitted than other strains (63), and is 
considered to be extraordinarily infectious due to its heightened lethality and clinical 
manifestations, which are far worse than any other strain (64, 65).  
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S. aureus Virulence Factors. The extended pathogenicity of S. aureus is largely the 
result of its repertoire of virulence factors, which allow the bacterium to invade, adhere 
to, and disseminate throughout host tissues and the bloodstream. S. aureus is known to 
possess a wider variety of virulence mechanisms than any other pathogen, and has 
become a model organism for the study of infectious disease and pathogenesis (66). 
Virulence determinants of S. aureus include various secreted toxins, hemolysins, 
nucleases, proteases, and adhesins (67). Typically, these exoproteins are secreted, 
although a number are characterized by being bound to the cell wall (68). The various 
types of S. aureus virulence determinants can be placed into two broad categories 
based on their function, and locality among the cell: adherence factors, and exoproteins, 
which are found attached the bacterial cell wall, or secreted into the extracellular 
environment, respectively. Adherence factors, also termed adhesins, mediate the 
adherence of S. aureus to a wide range of host cell surfaces and tissues, including host 
extracellular matrix proteins (69). Adhesins facilitate bacterial colonization and 
dissemination, and are essential to the pathogenic success of S. aureus. A major class 
of S. aureus adhesins are covalently anchored to the bacterial cell wall peptidoglycan 
via the enzyme sortase, and are termed MSCRAMMs (microbial surface components 
recognizing adhesive matrix molecules) (70, 71). There are approximately 30 different 
MSCRAMMs expressed by S. aureus; all of which recognize components of the host 
extracellular matrix and serum proteins, including collagen, fibronectin, and fibrinogen 
(72, 73). Distinctive proteins of the MSCRAMM family include the fibronectin-binding 
proteins A and B (FnbpA and FnbpB), the staphylococcal protein A (SpA), clumping 
factors A and B (ClfA and ClfB), and the collagen-binding adhesin (69, 74).  
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The secretion of exoproteins is a characteristic of nearly all S. aureus strains, and is a 
major factor of the bacterium’s superb ability to cause infection. The vast majority of S. 
aureus virulence factors are secreted, and include cytolytic toxins such as α-hemolysin 
and the Panton-Valentine Leukocidin; exotoxins such TSST-1 and the exfoliative toxins, 
which are the causative agents of toxic shock syndrome and staphylococcal scalded 
skin syndrome, respectively; and secreted enzymes such as proteases and 
staphylokinase (SAK), which activates plasminogen to form plasmin, an enzyme 
capable of digesting fibrin clots (75-77). Cytolytic toxins kill target cells by forming large 
pores in the plasma membrane, which causes leakage of intracellular contents and 
subsequently lyses the cell (78). The S. aureus alpha-toxin, also known as α-hemolysin 
(Hla), was the first pore forming β-barrell toxin to be discovered, and is the primary 
secreted cytolytic toxin (9). α-hemolysins insert into the lipid bilayer of red blood cells 
and form pores of amphiphilic beta-sheets, which not only cause profound cell leakage 
and lysis, but also cause secondary cellular reactions due to calcium influx through the 
pores (79).  PVL is also a β-pore forming toxin, which causes necrotizing pneumonia by 
destroying epithelial and mucosal leukocytes, and has been associated with increased 
virulence in several CA-MRSA strains (80).  
 
The Regulation of Virulence Factor Production. Staphylococcus aureus 
pathogenicity is a complex process involving various secreted and cell wall associated 
virulence determinants, which are expressed in response to environmental cues during 
different stages of infection (28, 81, 82). In order to coordinate differential expression of 
these factors, S. aureus encodes a series of global regulatory elements such as agr 
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(accessory gene regulator), sarA (staphylococcal accessory regulator), sae, sigB, and 
arl within its genome (83-86). These global regulators are essential to allow S. aureus to 
survive and adapt to harsh environmental conditions within the host, and mount a 
successful infection. Several regulatory loci interact, or “network” together to regulate 
the expression of a single gene, in order to ensure the gene of interest is only 
expressed under the correct conditions. For example, changes in protein expression 
during the transition from exponential to post exponential growth phase has been shown 
to be coordinately controlled by both the sarA and agr global regulons (82). The agr 
locus consists of an operon of four genes, agrDBCA, and is responsible for controlling 
the production of the majority of toxins and exoproteins in S. aureus during post-
exponential growth phase (87). The operon contains two transcripts, RNAII and RNAIII, 
which are driven by separate promoters and transcribed in opposite directions. RNAII 
comprises the messages for AgrD, AgrB, AgrC, and AgrA, which essentially correspond 
to a two-component signaling pathway activated by an auto-inducing peptide (AIP) 
ligand that senses and responds to increasing bacterial densities (88, 89). Upon 
mounting bacterial densities, AgrA, the response regulator, binds to the two promoter 
regions in agr: P2 for RNAII, and P3 for RNAIII (90-92). Once transcribed, the RNAIII 
molecule is responsible for regulating the expression of target genes, and also codes for 
the δ-lysin toxin (92). Overall, the agr locus is responsible for up-regulating the 
expression of exoproteins, while down-regulating the expression of colonization-related 
proteins such as adhesins, upon increasing bacterial densities (91). The sarA regulon 
promotes the synthesis of several adhesion proteins and toxins, while also encoding 
SarA, a 14.5-kDa DNA-binding protein which is proposed to activate biofilm formation, 
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and also helps mediate the expression of virulence factors either directly, by binding to 
gene promoters such as agr, hla, and spa, or indirectly by interacting with intermediary 
protein factors (91, 93, 94). Most importantly, however, sarA is responsible for the 
pleiotropic repression of protease activity in S. aureus, in contrast with agr, which 
initiates protease expression as previously described (95, 96).  
 
Proteases. Proteases are a class of degradative enzymes responsible for catabolizing 
proteins and peptides by hydrolyzing the peptide bonds, which link amino acids together 
in polypeptide chains. Proteases are ubiquitous throughout nature, and are essential for 
living organisms due to their integral roles in physiological and pathophysiological 
processes (97). In bacteria, these diverse enzymes can be localized to the cytoplasm, 
cell wall/membrane, and can also be secreted into the extracellular environment. The 
enzymatic actions of proteases can be divided into two groups: limited proteolysis, and 
unlimited proteolysis. In limited proteolysis, only one, or a limited number of peptide 
bonds are broken on a target protein, further leading to the activation or inactivation of 
that protein. In unlimited proteolysis, proteins are degraded into their amino acid 
constituents in a non-specific fashion (98, 99). Furthermore, proteases are separated 
into two groups based on their site of action: exopeptidases, or endopeptidases. 
Exopeptidases catalyze the cleavage of the terminal peptide bonds of proteins and 
peptides, releasing single amino acids or small peptides, while endopeptidases catalyze 
the cleavage of peptide bonds towards the center of proteins, away from their termini. 
Proteases can also be classified into four prominent groups based on their active site: 
serine proteases, aspartic proteases, cysteine proteases, and metalloproteases (100).  
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S. aureus Proteases. According to MEROPS, a database resource for proteases, the 
Staphylococcus aureus genome encodes approximately 165 known proteases to date. 
S. aureus is dependent upon these secreted, cytoplasmic, and membrane-bound 
proteases for various cellular functions, such as growth, metabolism, protein quality 
control, pathogenesis, regulatory, and housekeeping processes (101-104). In addition, 
some of these proteases are utilized by S. aureus as a mechanism to control its own 
pathogenesis. This occurs when secreted proteases cleave virulence factors in the 
extracellular environment in a nonspecific fashion (105). Because S. aureus is cleaving 
its own virulence factors, essentially, the result is an overall decreased virulence of the 
bacterium. This can be viewed as a system of checks and balances, which prevents S. 
aureus from becoming hyper virulent, and killing the host too quickly. S. aureus 
proteolytic enzymes have also been shown to self-target biofilm matrix constituents in 
an effort to regulate biofilm formation and dispersal (106). As such, the expression of 
proteases in S. aureus must be tightly regulated. Since many of the secreted proteolytic 
enzymes of S. aureus are toxins, if left unregulated, they can cause adverse toxicity, 
and damage the pathogen itself (107).  
 
There are 10 known secreted proteases of S. aureus, which include aureolysin (Aur), 
two cysteine proteases (ScpA, SspB), as well as seven serine proteases (SspA (V8), 
and SplABCDEF) (104, 108-111). These extracellular proteases have proposed roles in 
virulence, as well as biofilm regulation and detachment, and are important to S. aureus 
regulation of disease causation (104, 105, 108, 112). However, the four most prominent 
proteases secreted by S. aureus are Aur, ScpA, SspB, and the V8 protease, or SspA 
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(113). Most notable, the S. aureus metalloprotease aureolysin, is a very effective 
complement inhibitor, which functions to prevent phagocytosis and the perpetual killing 
of bacteria by neutrophils; and is also responsible for cleaving the principal complement 
protein C3 (114). This results in an overall dampening of the host immune response, 
which creates a less hostile environment in order for S. aureus to better survive and 
cause infection. The cysteine proteases ScpA and SspB, or staphopain A and B, 
respectively, have been shown to inhibit biofilm formation of S. aureus (106), with ScpA 
particularly capable of biofilm dispersal. The genes encoding SspA and SspB are 
cotranscribed, and both proteins must be cleaved in order to form fully functional 
enzymes (104, 113). The V8 protease, SspA, is very well characterized, and has been 
shown to play a large role in the progression of disease by cleaving surface protein A 
and a fibrinogen-binding protein (113, 115, 116).  
 
Aminopeptidases. Aminopeptidases are a class of exopeptidases that catalyze the 
cleavage of N-terminal amino acids from proteins and peptides, as opposed to 
carboxypeptidases, which act at the C-terminus of polypeptide chains (117). These 
enzymes are widely distributed throughout nature, and can be localized to the 
cytoplasm, subcellular organelles, as part of membrane components, as well as 
secreted into the extracellular environment (118). Currently, more than one hundred 
bacterial aminopeptidases have been purified and biochemically studied, while >40 
genes encoding aminopeptidases have been cloned and characterized (119). These 
diverse enzymes are classified based on their mechanism of catalysis, structure of 
active site, as well as substrate specificity (120). In terms of catalysis, they can be 
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divided into three groups: metallo-, cysteine-, and serine aminopeptidases, based on 
the amino acids present at their active site, and if a metal ion cofactor is required for 
catalysis. Further characterization of aminopeptidases can classify them as di-, tri-, or 
oligo- peptidases, which is not only dependent upon the number of N-terminal amino 
acids being cleaved (two, three, and four, respectively,) but can also be dependent 
upon the type of peptide substrates they act upon (dipeptides, tripeptides, and 
oligopeptides).  Aminopeptidases are known to perform critical cellular functions, with 
the best characterized being the methionine aminopeptidase (MAP), which shares 
homology throughout a diverse array of organisms, and functions by cleaving N-terminal 
methionine from newly synthesized proteins (121-123). The bacterial MAP in E. coli has 
been extensively characterized, and is essential for cell growth and survival (124). 
Aminopeptidases also play important roles in protein turnover, and are involved in 
regulatory functions (120). Protein turnover is important for cellular nutrition and 
metabolism by breaking down larger proteins into individual amino acid constituents for 
reuse in anabolic processes and pathways. Aminopeptidase N, found in E. coli, is 
involved in overall cytosolic protein degradation, and is responsible for the majority of 
the aminopeptidase activity in the cell (125). Bacterial aminopeptidases have even been 
found to play important roles in the food and dairy industry. For example, Lactococcus 
lactis is known for its ability to ferment milk into cheese, and is a staple starter culture of 
the food industry. However, L. lactis would not be able to grow in milk if not for its 
aminopeptidases, which degrade the milk protein casein into amino acid constituents 
the bacterium needs for metabolism (126). Another important aspect of aminopeptidase 
function is the integral role they play in bioactivation and inactivation pathways. N-
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terminal cleavage of a protein target by an aminopeptidase can result in the activation of 
a formerly inactivated protein precursor, which can then function in various cellular 
processes. However, these processes must be tightly controlled within the cell.  
Uncontrolled proteolytic activity results in the undesired cleavage of proteins and is 
detrimental to normal cellular physiology due to an imbalance in overall cellular 
homeostasis and signaling. Proteolytic control is achieved mostly by substrate 
specificity. As such, aminopeptidases can be ordered into two sub-groups based on 
their substrate specificity: broad or narrow (120). Aminopeptidases with broad substrate 
specificity are capable of acting upon a wide variety of protein and peptide targets, while 
narrow specificity aminopeptidases target a select group of protein substrates. Because 
of their importance, proteases have become an intriguing drug target for antimicrobial 
therapeutics.  
 
Of special interest, aminopeptidases have recently been shown to be involved in 
pathogenesis. In Fasciola hepatica, aminopeptidases are essential for invasion, 
acquisition of nutrients, and evasion of host immune responses (127). Moreover, two 
aminopeptidases, a leucine aminopeptidase and aminopeptidase T, were found to be 
upregulated in the proteomes of virulent strains of Streptococcus suis (128).  
Additionally, in Salmonella typhimurium, the aminopeptidase PepN modulates systemic 
infection when performed in a mouse model (129). Typically, virulence-related 
aminopeptidases are secreted outside of the cell, as opposed to the vast majority of 
characterized intracellular aminopeptidases involved in protein metabolism and 
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regulatory functions, establishing that these enzymes are extremely diverse in their 
functionality (130).  
 
S. aureus Aminopeptidases. There are thirteen putative aminopeptidase genes found 
in Staphylococcus aureus: pepA1, pepA2, pepA3, pepF1, pepF2, pepM, pepP1, pepP2, 
pepS, pepT1, pepT2, pepV, and pepZ (Shaw, unpublished observation), however, only 
one has been extensively characterized to date. LAP/PepZ, is a intracellular 
aminopeptidase which was first identified by our laboratory and found to be involved in 
S. aureus pathogenesis (131, 132). Significantly, PepZ was the first intracellular 
bacterial aminopeptidase found to be involved in virulence in Gram-positive bacteria. 
PepZ is part of the M17 family of metallo-peptidases, which are established as leucine 
aminopeptidases. This family of aminopeptidases has gained a large interest in recent 
years due to their involvement in virulence within V. cholera, P. aeruginosa, and S. 
typhimurium (129, 133, 134), and potential for vaccine development and therapeutic 
intervention in protozoan and parasitic diseases (127, 130). We previously found a pepZ 
mutant to be attenuated in virulence in both mouse systemic models of infection and 
localized abscess models carried out over a seven day infection period (130). Of 
importance, we have also shown that PepZ is not likely involved in nutrition and 
metabolism within S. aureus, as the pepZ mutant strain does not contain a growth 
defect as compared to the wild-type strain, and is also not required for growth in a 
peptide rich environment (130, 132). Additional studies carried out by our lab also 
concluded that PepZ has the highest activity against alanine and arginine residues, with 
optimal reaction conditions in the presence of MnCl2 at pH 7 (132). Although PepZ is the 
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only aminopeptidase to be extensively characterized in S. aureus, the function of two 
other aminopeptidases, PepM and PepS, can be moderately elucidated. The activity of 
PepM can be hypothesized, based on homology, to catalyze the cleavage of the N-
terminal methionine found on all nascent proteins (135-137). It is believed that the pepM 
gene is necessary to cell survival, from a number of studies assessing the essential 
gene content of S. aureus (138, 139). In addition, the crystal structure of the metallo-
aminopeptidase PepS from S. aureus has been elucidated, and previous studies 
suggest its physiological importance in bacterial survival (140, 141). Furthermore, an 
antisense RNA mutagenesis screen against AmpS/PepS from S. aureus was shown to 
cause a growth defect, and suggested PepS is involved in peptidoglycan metabolism 
(140-142).  
 
Project Aim. Previous studies have revealed the tremendous importance of both 
intracellular and extracellular bacterial aminopeptidases. These enzymes have been 
shown to have a remarkably dynamic range of functions, varying from cellular nutrition 
and metabolism, protein degradation and turnover, cellular regulation, and are even 
involved in virulence. However, with the exception of PepZ and PepM, very little is still 
known about the aminopeptidases of S. aureus. Therefore, elucidating the pathways in 
which aminopeptidases are employed in S. aureus, and the mechanisms by which 
these enzymes work, is essential to better understand their role in the cell and potential 
contribution to pathogenesis. The remaining eleven uncharacterized aminopeptidases in 
S. aureus are PepA1, PepA2, PepA3, PepF1, PepF2, PepP1, PepP2, PepS, PepT1, 
PepT2, and PepV. In this study, we aim to further characterize the eleven remaining 
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aminopeptidases listed above, and ascertain their role in S. aureus disease causation 
and pathogenesis. We plan to accomplish this goal by subjecting S. aureus mutant 
strains lacking a functional aminopeptidase gene to a variety of phenotypic, 
biochemical, and virulence related assays to determine characteristic differences as 
compared to a wild-type strain. Of special interest, we hope to identify other S. aureus 
aminopeptidases that are involved in virulence, and determine their mode of action 
within the cell. In order to determine the precise mechanisms in which aminopeptidases 
are involved in, it is necessary to identify the exact substrate targets these enzymes act 
upon. Therefore, we plan to utilize the cutting edge-proteomics tool, N-terminomics, 
which will allow us to compare wild-type and aminopeptidase mutant proteomes to 
establish differences in protein N-termini. It is possible these analyses could lead to an 
identification of potential drug targets and antimicrobial therapies in order to combat 
drug resistant S. aureus infection.  
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Materials and Methods 
 
Strains, Plasmids, and Primers. All bacterial strains, plasmids, and primers used 
during this study are listed in Table 1 and Table 2.  
 
Media and Growth Conditions. All media was prepared by using deionized water 
(diH2O) and autoclaved for sterility. Typically, S. aureus and E.coli strains were grown in 
100mL volumes (1:2.5 flask/volume ratio) of tryptic soy broth (TSB) or lysogeny broth 
(LB) overnight at 37oC shaking at 250 rpm. When necessary, antibiotics were added at 
the following concentrations: 100 µg ml-1 ampicillin (E. coli), chloramphenicol 5 µg ml-1 
(S. aureus), tetracycline 5 µg ml-1 (S. aureus), erythromycin 5 µg ml-1 (S. aureus), 
lincomycin 25 µg ml-1 (S. aureus), spectinomycin 5 µg ml-1 (S. aureus). To obtain a 
culture at a specific growth phase, 1mL of overnight culture was subcultured into fresh 
media, and synchronized by growing for 3 hours. The optical density (OD600) of the 
synchronized culture was then standardized to 0.05, unless otherwise stated, and 
allowed to grow until the desired growth phase was reached. 
 
Trypic Soy Broth (TSB) 
3% tryptic soy  
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Table 1. Strains and Plasmids 
Organism Strain Markers Source 
E. coli DH5α N/A Lab stocks 
S. aureus USA300 HOU  N/A Kolar, 2011 
S. aureus RN4220 N/A Kreiswirth, 1983 
S. aureus SH1000 N/A Horsburgh, 2002 
S. aureus 8325-4 N/A Lab stocks 
S. aureus USA300 JE2 pepA1 Tn* Mutant  Ery/Lin NARSA 
S. aureus  USA300 JE2 pepA2 Tn* Mutant  Ery/Lin NARSA 
S. aureus  USA300 JE2 pepA3 Tn* Mutant  Ery/Lin NARSA 
S. aureus USA300 JE2 pepF1 Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 JE2 pepF2 Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 JE2 pepT1 Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 JE2 pepT2 Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 JE2 pepP1 Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 JE2 pepP2 Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 JE2 pepV Tn* Mutant Ery/Lin NARSA 
S. aureus USA300 HOU pepS Silent Mutant N/A This study  
S. aureus USA300 HOU pepA1 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepA2 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepA3 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepF1 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepF2 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepT1 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepT2 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepP1 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepP2 Tn* Mutant  Ery/Lin This study 
S. aureus USA300 HOU pepV Tn* Mutant  Ery/Lin This study 
S. aureus  USA300 HOU pepT1 Tn* Mutant  Spc  This study 
S. aureus  USA300 HOU pepT1/pepT2 Tn* Double Mutant Ery/Lin/Spc This study 
S. aureus USA300 HOU pAZ106::pepT1-lacZ pepT1+ Ery/Lin This study 
S. aureus USA300 HOU pAZ106::pepT2-lacZ pepT2+ Ery/Lin This study 
S. aureus  USA300 HOU pMK4::pepT1- His Cm This study 
S. aureus USA300 HOU pMK4::pepT2- His Cm This study  
S. aureus USA300 HOU pMK4 empty vector Cm Lab stocks 
Plasmid pAZ106 Amp, Ery Lab stocks 
Plasmid  pMK4 Shuttle vector  Amp, Cm Lab stocks 
Plasmid pSPC Cm, Spc Lab stocks 
*List of bacterial strains and plasmids used during this study. Antibiotic resistance 
markers are: Ery – erythromycin; Lin – lincomycin; Spc – spectinomycin; Cm – 
chloramphenicol; Amp – ampicillin. Tn* indicates transposon mutants. 
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Table 2. Primer Sequences 
Primer  
 
Primer Sequence 
 
Site Name 
OL761 GAC CAT GCA GAG GAT GAT GC N/A R pAZ106 
OL1036 CCG CGC ACA TTT CCC CGA AA N/A R pMK4 
OL3106 AAA GGA TCC CAACAGTATCCATATGGC BamHI F pAZ106 pepT2 -lacZ 
OL3107 TTT TCT AGA GAT TTT GTA TAG GTA G XbaI R pAZ106 pepT2-lacZ 
OL3110 AAA GAA TTC TAT AAA ACT TTT AAC TTG AGA CG N/A F pMK4  pepT2 - His 
OL3111 TTT CCC GGG TTA GTG GTG GTG GTG GTG TTT CGA ATG TCG CGC N/A 
R pMK4 
pepT2 - His 
OL3112 AAA GAA TTC TTA GAA GTT ACA CTG ATT TCA GG  N/A F pMK4 pepT1 - His  
OL3113 TTT CCC GGG TTA GTG GTG GTG GTG GTG GTG ATT TTC AGC G N/A 
R pMK4 
pepT1 - His 
OL3122 AAA TCT AGA CGG TAG ATT TAG AGT TTG GAA AAG TTG GCG XbaI 
F pAZ106 
pepT1-lacZ 
OL3123 TTT GGA TCC TAG TAT AAG CAA AAT CAG CAT TGA AGC GG BamHI 
R pAZ106 
pepT1-lacZ 
OL3088  TGG TGT GAA TGG TGT TAC CG  F pepV qPCR 
OL3089 CAC CTC GAT GTT GAA TTG CTT C  R pepV qPCR  
OL3090 TTG GTA TGG GCG TTT CTG G  F pepT2 qPCR 
OL3091 CAC ATG AAG CAC CGT CTT TTG   R pepT2 qPCR 
OL3092 AGGTGATACTGCAACTGGTG  F pepP2 qPCR 
OL3093 TGAAATGTAGCTTCCATCACCAG  R pepP2 qPCR  
OL3094 TGA ATC TTT AAA ACA AGG TGC TAC AG  F pepA1 qPCR 
OL3095 CTG GTT CTA TCA CTC TAC AAT CTG G  R pepA1 qPCR  
*List of primer sequences used during this study. Restriction sties are underlined. 
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Top Agar 
3% tryptic soy   
0.7% agar  
 
Lysogeny Broth (LB) 
Tryptone  10 g L-1 
NaCl   10 g L-1 
Yeast      5 g L-1 
 
Peptide-Rich Media 
10% dried skim milk reconstituted in diH2O, and autoclaved for 15 minutes.  
 
Biofilm Media 
3% TSB 
3% NaCl  
0.5% dextrose  
 
Chemically Defined Media  
 
Solution 1 
L-Aspartic acid     3g 
L-Alanine     2g  
L-Arginine    2g 
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L-Cystine              1g 
Glycine              2g 
L-Glutamic acid    3g 
L-Histidine    2g 
L-Isoleucine    3g 
L-Lysine    2g 
L-Leucine              3g 
L-Methionine    2g 
L-Phenylalanine   2g 
L-Proline    3g 
L-Serine    2g 
L-Threonine    3g 
L-Tryptophan   2g 
L-Tyrosine    2g   
L-Valine    3g 
Na2HPO4           140g  
KH2PO4             60g 
 
Make up to 1400mL with diH2O, and autoclave.  
 
Solution 2 
Biotin        0.4 mg 
D-Pantothenic acid          8 mg 
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Pyridoxal         16 mg 
Pyridoxamine diHCl       16 mg 
Riboflavin           8 mg 
Nicotinic acid          8 mg 
Thiamine HCl                   8 mg 
 
Make up to 400mL with diH2O, and filter sterilize.  
 
Solution 3 
Adenine sulphate                800 mg 
Guanine HCl                          800 mg  
 
Dissolve in 0.1 M HCl and make up to 2000mL with 0.1 M HCl, then autoclave. 
 
Solution 4  
CaCl26H2O              1g 
MnSO4                           500 mg  
FeNH4(SO4)212H2O               600 mg 
 
Dissolve in 0.1 M HCl and make up to 100mL with 0.1 M HCl.  
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Solution 5  
Glucose       200 mg 
MgSO47H2O                                10g 
 
Make up to 2000mL with diH2O, and autoclave.  
 
Amino Acid Limiting Media 
Combine the following solutions: 
Solution 1         70mL 
Solution 3          50mL 
Solution 4                      1mL 
diH2O                  759mL 
 
Autoclave the media and cool to 55o, then add the following: 
 
Solution 5                               100mL  
Solution 2                                 20mL 
 
Buffers and Solutions. All buffers were prepared using diH2O, autoclaved, and stored 
at room temperature, unless otherwise stated.  
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Phosphate Buffered Saline (PBS) 
0.8% sodium chloride  
0.02% potassium chloride  
0.14% disodium phosphate 
0.02% potassium dihydrogen phosphate  
pH 7.4  
 
Phage Buffer    
MgSO4               1 M 
CaCl2                                        4 mM 
NaCl                                       5.9 g L-1 
Gelatin          1 g L-1 
Tris-HCl, pH 7.8                50 mM 
 
UDS Buffer  
Urea             6 M 
DTT                                          5 mM 
Tris-HCl, pH 8.0                     50 mM 
SDS                                  1% 
 
Polyacrylamide Stacking Gel  
Acrylamide                              650 µl 
0.5 M Tris-HCl, pH 6.8          1.25mL 
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10% SDS                                  50 µl 
10% APS                                  25 µl 
TEMED                                       5 µl 
diH2O                                         3m 
 
Polyacrylamide Separating Gel  
Acrylamide                                 4mL 
1.5 M Tris-HCl, pH 8.8            2.5mL 
10% SDS                                100 µl 
10% APS                                  50 µl 
TEMED                                     10 µl 
diH2O                                      3.3mL 
 
2X Hemolysin Buffer (HA) 
10% NaCl                 8.5mL 
1 M CaCl2           2mL 
 
Make up to 50mL with diH2O.  
 
ABT Buffer 
NaCl      100mM 
K2HPO4                                  60mM 
KH2PO4                                  40mM 
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Triton X-100                             0.1% 
 
ABTN Buffer 
0.4 M Na2CO3      0.5mL 
ABT        0.5mL 
 
TE Buffer 
Tris-HCl, pH 8.0      10mM 
EDTA                    1mM 
 
Reagents. All reagents used are listed in Table 3.  
 
Bacterial Constructs. 
 
Construction of the pepT-lacZ Reporter Fusion Strains  
The pepT1-lacZ reporter fusion strain (Table 1) was constructed using the forward 
primer OL3122 and the reverse primer OL3123 (Table 2); to PCR amplify the pepT1 
promoter region. The pepT2-lacZ reporter fusion strain (Table 1) was constructed using 
the forward primer OL3106, and the reverse primer OL3107 (Table 2); to PCR amplify 
the pepT2 promoter region. The resulting fragments were then separately cloned into 
the multiple cloning site of the suicide plasmid pAZ106, upstream of the promoterless 
lacZ gene. The constructs were confirmed in E.coli, followed by electroporation into  
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Table 3. List of Chemical Stressors 
Agent 
 
Agent 
 
Concentration 
 
Concentration 
Stress 
 
Stress 
Penicillin-G 10mg/ml Antibiotic 
Vancomycin 5mg/ml Antibiotic 
Phosphomycin 4mg/ml Antibiotic 
Spectinomycin 5mg/ml Antibiotic 
Ampicillin 1mg/ml Antibiotic 
Tetracycline 5mg/ml Antibiotic 
Erythromycin 5mg/ml Antibiotic 
Lincomycin 15mg/ml Antibiotic 
Kanamycin 50mg/ml Antibiotic 
Neomycin 5mg/ml Antibiotic 
Rifampicin 1.5mg/ml Antibiotic 
Chloramphenicol 10mg/ml Antibiotic 
Oxacillin 10mg/ml Antibiotic 
Mupirocin 2mg/ml Antibiotic 
HCL 1M Acid 
Phosphoric Acid 85% Acid 
TCA 50% Acid 
Formic Acid 88% Acid 
Acetic Acid 1% Acid 
Sulphuric Acid 2M Acid 
Nitric Acid  6M Acid 
NaCl 5M Osmotic 
Glucose 1M Osmotic 
Sodium Hydroxide 1M Alkaline 
SDS 10% Detergent 
Triton X-100 1% Detergent 
Tween-20  1% Detergent 
N-lauroyl sarcosine 1M Detergent 
Ethanol 100% Alcohol 
Methanol 100% Alcohol 
Isopropanol 100% Alcohol 
4-methyl methanesulfonate 1M DNA Damaging 
Ethidium Bromide 10mg/ml DNA Damaging 
Hydrogen Peroxide 30% Oxidative 
Menadione 1% Oxidative 
Pyrogallol 50mg/ml Oxidative  
Diamide 1mg/ml Disulfide 
Berberine Cl 1mg/ml Misc. 
Peracetic Acid 4M Misc. 	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Table 3. (Continued) 	  
EDTA 10mg/ml Misc. 
DTT 1mM Misc. 
Triclosan 5mg/ml Misc. 
Acridine Orange 1mg/ml Misc. 
Crystal Violet  1% Misc.  
* List of chemical stressors used for lacZ transcriptional and stress profiling 
experiments. 
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S. aureus strain RN4220, and subsequently transduced into the wild-type strain via 
phi11 bacteriophage (Φ11). PCR, and DNA sequencing confirmed both reporter fusion 
strains. 
 
Construction of the His Tagged PepT Complement Strains  
The pepT1 complement strain (Table 1) was created by using forward primer OL3112, 
and the reverse primer OL3113 (Table 2), to PCR amplify a fragment containing the 
pepT1 gene and promoter region, followed by additional nucleotides prior to the stop 
codon which, once translated, would result in a six histidine tag at the C-terminus of the 
protein. Additionally, The pepT2 complement strain (Table 1) was created by using 
forward primer OL3110, and the reverse primer OL3111 (Table 2), to PCR amplify a 
fragment containing the pepT2 gene and promoter region, followed by additional 
nucleotides prior to the stop codon which, once translated, would result in a six histidine 
tag at the C-terminus of the protein. The resulting pepT-His6 fragments were separately 
cloned into the multiple cloning site of the shuttle vector, pMK4. The constructs were 
confirmed in E.coli, followed by electroporation into S. aureus strain RN4220, and 
subsequently transduced into the wild-type strain via phi11 bacteriophage (Φ11). PCR, 
and DNA sequencing confirmed both complement strains.  
 
Construction of pepT1/pepT2 Double Mutant  
The pepT1/pepT1 double mutant strain was created by utilizing the pSPC vector, a 
genetic exchange plasmid designed to incorporate alternate antibiotic resistance 
markers while subsequently removing the erythromycin cassette found in the bursa 
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aurealis transposon (143, 144). As such, the pSPC plasmid was transduced into the 
pepT1-Ery marked mutant strain, and the erythromycin resistance cassette was 
replaced with spectinomycin resistance, as described previously (145), creating a 
pepT1 spectinomycin marked mutant (Table 1). The pepT1-Spc marked mutant was 
then confirmed by PCR, and transduced into the pepT2-Ery marked mutant via Φ11. 
The double PepT enzyme mutant was selected for based on resistance to 
spectinomycin (pepT1) and erythromycin (pepT2), with susceptibility to chloramphenicol 
(indicating loss of the pSPC plasmid), and the construct confirmed by PCR and DNA 
sequencing.  
 
Virulence Assays. 
 
Survival in Whole Human Blood 
Synchronized cultures of wild-type, pepT1, pepT2, pepT1/T2 mutant, as well as their 
respective pepT1 and pepT2 complement strains, were grown to exponential growth 
phase, and subsequently washed three times in PBS. Cultures were then separately 
inoculated into 1mL of whole human blood obtained from Bioreclamation, at an OD600 of 
0.05, and incubated for 4h at 37°C with shaking. Samples were withdrawn after 4h, and 
plated on TSA to determine percent recovery compared to the inocula.  
 
THP-1 Macrophage Infection  
The THP-1 macrophage infection was carried out as described previously (146). As 
such, THP-1 human monocytes were grown at 37oC, with 5% CO2, in RPMI medium 
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with L-glutamine and 10% fetal bovine serum. Once a desired density was reached, the 
macrophages were treated with 80nM PMA (phorbol 12-myristate 13 acetate), to induce 
the cells to differentiate and become adherent. After 48h incubation with PMA, the THP-
1 cells were then seeded into a 96 well microtiter plate at a density of 106 cells/well, and 
subsequently infected with 106 CFU/mL of the wild-type, pepT1, pepT2, and pepT1/T2 
mutant bacteria. Plates were then centrifuged for 10 minutes at 450 rpm, and 
phagocytosis was allowed to progress for 1h at 37°C with 5% CO2. Following 
phagocytosis, the cells were washed three times with PBS, and treated with 30 µg mL-1 
of gentamycin in culture media for 1h at 37oC with 5% CO2 to kill remaining extracellular 
bacteria. To determine the amount of bacteria phagocytized, cells were washed three 
times in PBS and treated with 500 µl of 0.5% Triton X 100 in PBS in order to lyse THP-1 
macrophages. The cellular lysates were then diluted, and plated on TSA to conclude 
percent phagocytized. To determine intracellular survival after 24h, the experiment was 
performed as described, however, following treatment with 30 µg mL-1 of gentamycin for 
1h, the media was removed, and replaced with media containing 5 µg mL-1 of 
gentamycin. Plates were incubated at 37oC with 5% CO2 for an additional 24h, before 
treatment with 500 µl of 0.5% Triton X 100 in PBS in order to lyse THP-1 macrophages. 
The cellular lysates were then diluted, and plated on TSA to conclude the percent of 
intracellular survival.  
 
Co-Infection Models of Systemic Infection 
These experiments were carried out as described previously (147). Ten, 6-week-old 
female mice were separately co-infected intravenously with 100 µl (a total of 5 x 10! 
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CFU/mL) of the wild-type and either the pepT1, pepT2, or pepT1/T2 double mutant 
strains in a 1:1 ratio. The infection was allowed to progress for 7 days and the mice 
were subsequently euthanized. The kidneys, brain, heart, liver, lungs, and spleen were 
harvested, homogenized in 3mL sterile PSB, and serially diluted in PBS.  Dilutions were 
then plated, in duplicate, on TSA and TSA containing erythromycin, incubated overnight 
at 37oC, and bacterial loads determined by calculating CFU/organ.  
 
Biofilm Assay  
To assess biofilm formation, overnight cultures of wild-type, SH1000, 8325-4, pepT1, 
pepT1 complement, pepT2, pepT2 complement, pepT1/T2, were separately grown, in 
triplicate, in biofilm media supplemented with 0.5% dextrose and 3.0% NaCl. 96-well 
microtiter plates were then treated with 20% human plasma (5 mL lyophilized plasma 
re-suspended in 25 mL carbonate/bicarbonate buffer), and incubated overnight at 4oC. 
The following day, the plasma was removed by gentle aspiration, and the cultures 
diluted 1:200 in sterile biofilm media. Cultures were then added in 150 µl volumes into 
the microtiter plates, and incubated statically at 37oC for 24 hours. Following incubation, 
the cultures were aspirated from each well, and the wells subsequently washed three 
times with sterile PBS. Biofilms were fixed with 100% ethanol, air dried, and then 
stained by adding 200 µl of crystal violet for 2 minutes. Once the crystal violet was 
eluted, the wells were again washed three times with sterile PBS, and allowed to dry 
overnight. Adding 100% ethanol to the wells and measuring absorbance levels of the 
eluted crystal violet, quantified Biofilm growth.  
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Hemolysin Assay 
Hemolysis experiments were carried out as described previously (148), with the 
following modifications. Overnight cultures of wild-type, pepT1, pepT2, and pepT1/T2 
mutant strains were measured for OD600, and 1mL aliquots of each was removed, and 
placed into a fresh 1.5mL eppendorf, followed by centrifugation at 12,000 rpm for 2 
minutes.  Equal amounts of the resulting supernatants were mixed with 2X hA buffer in 
a 1:1 ratio, and 25 µl of whole human blood was added. Suspensions were mixed gently 
by inversion, incubated at 37oC for 40 minutes with agitation, and subsequently 
centrifuged at 5,500 rpm for 1 minute. Supernatants were transferred to a 96-well 
microtiter plate, and the OD543 measured against a blank of TSB + HA buffer + blood, 
and treated as above. Hemolysin units were calculated by the following equation: 
(OD543 x 100) / (volume of supernatant (mL) x time (min) x OD600).  
 
Growth and Nutritional Assays. 
 
Growth Analysis in Peptide-Rich Media  
Exponentially growing wild-type cells, as well as those for each of the eleven 
aminopeptidase mutant strains, were separately inoculated, in triplicate, into 10% skim 
milk at a starting OD600 of 0.05, and allowed to grow for 24h at 37°C with shaking. 
Samples were taken every hour, and serially diluted in sterile PBS, before plating in 
duplicate onto tryptic soy agar (TSA) to assess cell viability by CFU/mL. 
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Growth Analysis in Amino-Acid Limiting Chemically Defined Media  
Exponentially growing wild-type, pepT1, and pepT2 mutant strains were first grown 
overnight on CDM agar, then separately inoculated, in triplicate, into amino acid limiting 
CDM media. Cultures were allowed to grow for 7 days at 37oC static, as well as with 
shaking. To determine percent survival, samples were taken daily, serially diluted in 
sterile PBS, plated in duplicate on TSA, and CFU/mL calculated. 
 
Anaerobic Growth Analysis  
Exponentially growing wild-type, pepT1, pepT2, and pepT1/T2 mutant strains were 
separately inoculated, in triplicate, in TSB, and allowed to grow for 24h anaerobically. 
Cultures were grown in two conditions: 37o C with shaking, as well as 37o C statically. 
To determine percent survival, samples were taken at 0h, 3h, 6h, 9h, and 24h, serially 
diluted in sterile PBS, plated in duplicate on TSA, and CFU/mL calculated. Plate based 
profiling of anaerobic growth was determined using TSA, sheeps blood agar, casein 
nutrient agar, nuclease agar, amino acid limiting media, as well as mannitol salt agar 
(MSA). Agar plates of each were separately inoculated using three isolated bacterial 
colonies from the respective wild-type, pepT1, pepT2, and pepT1/T2 mutant strains, 
and grown in parallel under both aerobic and anaerobic conditions at 37oC overnight. 
 
Phenotypic Assays. 
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Plate Based Stress Assays 
TSA agar plates were overlaid with 5 mL of 0.07% top agar containing equal volumes of 
wild-type, pepT1, pepT2, or pepT1/T2 mutant strains at a 1:1000 dilution. Chemical 
stressors (Table 3) were subsequently applied in 10µl volumes to 7mm round sterile 
Whatman Paper filter disks, which were placed, in triplicate, on the top agar. Plates 
were incubated for 24h at 37oC and screened for differences in susceptibility to the 
various chemical compounds as compared to the parental strain by measuring zones of 
inhibition. The chemical stressors were as follows: penicillin-G, vancomycin, 
phosphomycin, spectinomycin, ampicillin, tetracycline, erythromycin, lincomycin, 
kanamycin, neomycin, rifampicin, chloramphenicol, oxacillin, mupirocin, HCL, 
phosphoric acid, TCA, formic acid, acetic acid, sulphuric acid, nitric acid, NaCl, glucose, 
sodium hydroxide, SDS, Triton X-100, Tween-20, N-lauryl sarcosine, ethanol, methanol, 
isopropanol, 4-methyl methanesulfonate, ethidium bromide, hydrogen peroxide, 
menadione, pyrogallol, diamide, berberine Cl, peracetic acid, EDTA, and DTT.  
 
Triton X-100 Autolysis Assays  
Triton X-100 induced autolysis assay was performed, as described previously (149, 
150). Exponentially growing cultures of wild-type and pepT1/T2 double mutant strains 
were standardized to an OD600 of 0.5, and grown until an OD600 of 1.5 was reached. 
Cells were then pelleted, washed three times with sterile PBS, and re-suspended in 
sterile PBS containing 1.5% Triton X-100. Cultures were incubated with shaking at 
37oC, and the OD600 was measured every 20 minutes for a total of 140 minutes, with a 
final measurement taken at 24 hours. Experiments were performed in triplicate and the 
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ODs measured in duplicate. Percent survival was determined by the OD600 of each time 
point as compared to the initial OD600 measurement. 
 
Membrane Integrity Assays 
Synchronized cultures of wild-type, pepT1, and pepT2, mutant strains, were grown to 
exponential growth phase, and subsequently washed three times in 5mL of sterile PBS. 
A starting sample was taken, serially diluted, and plated in duplicate on TSA, and 
CFU/mL calculated. Oleic acid (0.1%) or toluene (1.5%) was then added, and cultures 
were allowed to grow for 1h at 37oC with shaking. To determine percent survival, 
samples were taken every 15min, and CFU/mL calculated as described.  
 
Oxidative Stress Assay 
Synchronized cultures of exponentially growing wild-type, pepT1, and pepT2 mutant 
strains were subjected, in triplicate, to the addition of 150mM H2O2, and allowed to 
incubate for 10 minutes at room temperature. To determine percent survival, samples 
were taken at 0, 5, and 10 minutes, serially diluted in sterile PBS, and plated in 
duplicate on TSA, and CFU/mL calculated. 
 
Transcriptional Assays. 
 
Quantitative Real-Time PCR  
Cellular mRNA was isolated as described previously (151). To 5mL of synchronized 
cultures in exponential growth phase, 5mL of sterile PBS was added. Cells were then 
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centrifuged at 4,150 rpm for 10 minutes, the supernatants discarded, and the remaining 
bacterial pellets frozen at -80oC overnight. The following day, cells were resuspended in 
100 µl of TE buffer, and lysed by bead beating for 40 seconds. Samples were then 
treated with 700 µl of β-mercaptoethanol, followed by the addition of 700 µl of RLT 
buffer, and lysed by an additional round of bead beating for 40 seconds. The samples 
were then centrifuged at 4,150 rpm for 1 minute, and 600 µl of the supernatant 
collected, and added to 900 µl of 100% ethanol to provide ideal binding conditions. The 
samples were then added to an RNeasy spin column, and treated with 350 µl of RWI. 
The columns were washed with 500 µl RPE buffer, and eluted into 50 µl RNase-free 
H2O, then treated with DNase at 37oC for 40 minutes. Per the manufacturer’s protocol, 
cDNA was then synthesized by utilizing the iScript cDNA kit. Quantitative real-time PCR 
was carried out as three independent replicates of 20 µl reactions containing 10 µl syber 
(2X master mix), 1 µl forward primer, 1 µl reverse primer, 2 µl cDNA, and 6 µl H2O. The 
primers used were specific for the downstream genes of pepA1 (OL3094, OL3095), 
pepP2 (OL3092, OL3093), pepT2 (OL3090, OL3091), and pepV (OL3088, OL3089), 
while endogenous control primers were used for 16s rRNA gene.  
 
β-galactosidase Activity Assays 
The pepT-lacZ reporter gene fusions were separately plated on TSA containing 25 µl of 
5 µg ml-1 erythromycin, and 25 µl of 40 µg ml-1 X-GAL. Plates were incubated at 37oC 
overnight, and screened for blue colonies. Three independent colonies were then 
selected from each plate, inoculated into TSB, and grown at 37oC. To deduce levels of 
expression, samples in 100 µl volumes were taken, in duplicate, every hour for 8h, and 
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again at 24h, placed into a fresh 1.5mL eppendorf tube, and stored at -80oC until 
analysis. Once analysis could be conducted, the samples were removed from the 
freezer and allowed to thaw on ice. Samples were resuspended in 0.5mL of ABT buffer, 
then 100 µl of 4-MUG (4 mg/mL in DMSO) was added, and samples were incubated at 
25oC for 60 minutes in the dark. Immediately after incubation, 0.5mL of 0.4 M NA2CO3 
was added to stop the reaction, and the samples then mixed by inversion. Fluorescence 
was measured using a BioTek Synergy 2 plate reader. The β-galactosidase activity was 
determined using the following equation. (((Fluorescence –Background fluorescence) –
C) / M) x ((A / B) / (T x OD600 x V)) = β-galactosidase units mL-1 OD600-1 min-1 (C = Value 
of intercept of calibration curve (Determined from fluorescence readings of known 
concentrations of 4MU), M = Gradient of the calibration curve (Determined from 
fluorescence readings of known concentrations of 4MU), A = Volume of the assay (1.1 
mL total of 500 µl ABT, 500 µl 0.4 M Na2CO3 and 100 µl of 4-MUG), B = Volume in 
Microtiter well (0.225 mL), T = Reaction time (60 min), V = Volume of cells originally 
sampled (0.1 mL)). 
 
Transcriptional Disk Diffusions  
To assess transcription induction, TSA agar plates were overlaid with 5 mL of 0.07% top 
agar containing 3 µg/ml-1 of X-GAL, and either the pepT1-lacZ or pepT2-lacZ fusion 
strains at a 1:1000 dilution. Chemical stressors (Table 3) were subsequently applied as 
previously described for stress analysis, in 10µl volumes to 7mm round sterile Whatman 
Paper filter disks, which were placed, in triplicate, on the top agar. Plates were 
incubated for 24 h at 37oC and screened for the presence of blue halos, which is a 
41 
result of the cleavage of X-GAL by β-galactosidase (152), indicating induced 
expression. To assess transcriptional repression, the chemical stressor disk diffusion 
assays were performed as described above, with top agar containing 4 µg/ml-1 of X-GAL 
and either the pepT1-lacZ or pepT2-lacZ fusion strains at a 1:1000 dilution. Plate were 
incubated for 24 h at 37oC and screened for the presence of yellow halos, indicating the 
repression of transcription due to no X-GAL being cleaved by β-galactosidase. 
 
Proteomic Assays. 
 
Protein Extraction  
Secreted, cytoplasmic, and intracellular proteins were harvested from 100mL 
synchronized cultures of wild-type, pepT1, and pepT2 mutant grown to the desired time 
point.  Following centrifugation for 10 minutes at 4150 rpm, the supernatants were then 
collected in 50 µl fractions, and measured for protein concentration using a Pierce 660 
nm protein assay kit (supernatant protein fraction). The remaining pellets were 
resuspended in sterile PBS, and 1mL of the suspension placed into a fresh 50mL tube. 
Lysostaphin (10 µl) was then added, and the samples were incubated at 37oC for 30 
minutes in a waterbath. Following, 2 µl of DNAseI enzyme was added, and the samples 
incubated in a waterbath for an additional 30 minutes at 37oC. The samples were then 
centrifuged at 12,000 rpm for 5 minutes, and the supernatants collected and measured 
for protein concentration (intracellular protein fraction). The remaining pellet was 
resuspended in 100 µl UDS buffer, and measured for protein concentration (cell 
wall/membrane protein fraction).  
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Western Blot Analysis  
Secreted, cytoplasmic, and intracellular proteins were harvested from 100mL 
synchronized cultures of pMK4::wild-type, pMK4::pepT1-His6, and pMK4::pepT2-His6 
tagged cells, grown to the desired time point. As a negative control, proteins were 
harvested from a wild-type strain containing an empty pMK4 vector (EV). Standardized 
amounts of protein were resolved on an SDS-page gel, followed by transfer to a PVDF 
membrane. His6 tagged proteins were probed for using an anti-His antibody, detected 
using a secondary antibody, and then visualized by X-ray exposure.  
 
Desalt 
MacroSpin columns were activated by pipetting 500 µl of acetonitrile (ACN) onto the 
column, and centrifuged at 1,100 rpm for 1 minute (each centrifugation follows these 
parameters). Flow-through was discarded, and the column blotted dry using a Kim wipe. 
The columns were then equilibrated by adding 500 µl of 0.1% formic acid, and the flow-
through again discarded. The addition of formic acid and centrifugation was repeated, 
for a total of two additions of 0.1% formic acid, and the flow-through discarded. Protein 
samples were then added to the MacroSpin columns, centrifuged, and the flow-through 
discarded. Columns were washed by pipetting 500 µl of 0.1% formic acid, and the flow-
through discarded. This step was repeated, for a total of two column washes. Samples 
were then eluted into fresh 2mL eppendorf tubes by pipetting 250 µl of 90:10 ACN:H2O 
onto the columns, and vacuum dried, and stored at 4oC until analysis.  
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N-Terminomics  
We first collected 4 mg/ml of cytoplasmic proteome of our wild-type, pepT1, and pepT2 
mutant strains (Fig. 1A), in triplicate, as described by us previously (153). Dry 
guanidinium hydrochloride was added to a 6 M final concentration to inactivate 
proteases, and disulfides reduced by adding DTT to a 10mM final concentration. The 
samples were then vortexed, and incubated on a 95oC heat block for 10 minutes. Once 
the samples were cooled to room temperature, cysteines were alkylated by adding 
iodoacetamide to a 30mM final concentration, and the samples incubated in the dark, at 
room temperature, for 30 minutes.  Lysine residues in the samples were then converted 
to homoarginines by adding 0.5 M o-methylisourea (final concentration), and incubated 
overnight at 4oC to allow for the complete modification of lysine residues without 
reacting with N-termini. The following day, PD-10 columns were equilibrated with 25mL 
of 8 M urea, and the protein samples were then buffer exchanged into 8 M 
urea/HEPES. The desalted samples were collected, and N-terminal amines were then 
tagged by adding 5 mM sulfo NHS-SS-biotin for 1 hour at 37oC (Fig. 1B). Adding 1 M 
ammonium bicarbonate pH 7.8, to reach a final concentration of 50mM, terminated the 
tagging reactions. The samples were subsequently treated with a 40mM final 
concentration of 1 M stock hydroxylamine for 15 minutes at 37oC to remove any low 
frequency side reactions that may have occurred between the biotin and 
serine/threonine residues. The samples were buffer exchanged again into an 8M 
urea/HEPES buffer. Protein samples were then diluted to 2 M urea with 50mM 
ammonium bicarbonate, and digested with 5 µg of modified sequence grade trypsin at 
37oC overnight (Fig. 1C). The following day, 500 µl of high-capacity neutravidin resin 
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was added to each sample in order to bind the biotinylated N-terminal peptides. 
Samples were incubated at 4oC with rocking for 30 minutes, then loaded onto 2mL 
polystyrene columns, and washed extensively with 2M urea/HEPES buffer. Three 
column volumes of 50mM ammonium bicarbonate were then added, and the samples 
collected by pipetting out the resin left on the top of the column using 1mL of 50mM 
ammonium bicarbonate, into sterile 1 ml microcentrifuge tubes. The biotin tags were 
removed by adding DTT to a 50mM final concentration, and the samples were 
subsequently incubated at 37oC with rocking for 30 minutes. Samples were then eluted 
through Micro-Bio chromatography columns into 1 ml microcentrifuge tubes (Fig. 1D), 
desalted as previously described, and vacuum dried for mass spectrometry analysis. 
The N-terminomic samples were analyzed by HPLC-MS/MS using the Orbitrap XL. After 
analysis, the data was searched on MASCOT against a complete S. aureus proteome. 
The data files were then loaded onto Scaffold in order to evaluate peptide and protein 
identifications.  A normalized T-Test of the total ion current (TIC) was then performed 
against the total identified protein data-set with a significance level threshold of p <= 
0.05. The abundance of N-terminal peptides identified for each protein was averaged 
from triplicate samples of wild-type and mutant proteomes. This average was then used  
to determine significant differences in N-terminal peptide abundance from the mutant 
proteomes as compared to the wild-type.  
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Figure 1. N-Terminomics Workflow. Example of the N-terminomics workflow with a 
wild-type, and mutant strain. The thick blue lines represent a protein substrate target of 
a single aminopeptidase, while the thick orange lines represent a protein that is not a 
target of an aminopeptidase. Cytoplasmic proteomes of wild-type, and mutant (pepT1, 
and pepT2) were collected, in triplicate (A). As shown above, the N-terminal amine of 
the wild type substrate target (thick blue line) has been cleaved and is thus shorter, 
while the substrate target in the mutant has an intact N-terminus, due to the absence of 
the aminopeptidase. Proteins that are not a target of the aminopeptidase, (thick orange 
line) stay the same size. N-terminal amines were then tagged by adding 5 mM sulfo 
NHS-SS-biotin for 1 hour at 37oC (B). Protein samples were then diluted, and digested 
with 5 µg of modified sequence grade trypsin at 37oC overnight (C). High-capacity 
neutravidin resin was added to bind biotinylated peptides, and the samples were 
washed extensively. Biotin tags were removed by adding DTT, and the samples were 
then eluted through Micro-Bio chromatography columns into 1 ml microcentrifuge tubes 
(D), desalted, and vacuum dried for HPLC-MS/MS analysis.  
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Results 
 
Exploration of S. aureus Aminopeptidases. From a bioinformatics analysis previously 
performed by our lab, S. aureus has thirteen putative aminopeptidase enzymes 
encoded within its genome (Table 4). Of these thirteen, a mutation in one (AmpS/PepS) 
was previously identified as having a growth defect in an anti-sense mutagenesis 
screen (154). Additionally, our lab has characterized LAP/pepZ, a leucine 
aminopeptidase necessary for virulence in S. aureus (131). The role of an additional 
aminopeptidase can be hypothesized based on homology: PepM, is a methionine 
aminopeptidase that is well studied in many organisms as an essential protein 
responsible for cleaving N-terminal methionine residues from newly synthesized 
proteins and peptides (123). In order to explore the role of the uncharacterized eleven 
aminopeptidases (including PepS) in S. aureus, we utilized the Nebraska Transposon 
Mutant Library (NTML), which consists of bursa aurealis transposon insertions within all 
non-essential genes in the S. aureus genome (144). 
 
Operon Structure Analysis and Mutagenesis of the NTML Aminopeptidase 
Mutants. Mutations for the eleven uncharacterized aminopeptidases were first 
transduced from the S. aureus JE2 background to the USA300 Houston wild-type strain 
(our lab strain of choice). Before performing work with these mutants, the operon 
structures were analyzed from existing lab RNAseq data (147), in order to determine 
47 
Table 4. The Aminopeptidases of S. aureus 
Name Classa Familyb Annotationc Polarityd 
Name Classa Familyb Annotationc Polarityd 
pepA1 Aminopeptidase M42.001 SAUSA300_1691 Yes 
pepA2 Aminopeptidase M42.001 SAUSA300_2400 No 
pepA3 Aminopeptidase M42 SAUSA300_1261 No 
pepF1 Oligopeptidase M03.007 SAUSA300_0902 No 
pepF2 Oligopeptidase M03 SAUSA300_1278 No 
pepT1 Tripeptidase M20.003 SAUSA300_0727 No 
pepT2 Tripeptidase M20.018 SAUSA300_1460 No 
pepM Aminopeptidase M24.001 SAUSA300_1869 N/A 
pepP1 Aminopeptidase M24.006 SAUSA300_1654 No 
pepP2 Dipeptidase M24.008 SAUSA300_1491 No 
pepS Aminopeptidase M20.005 SAUSA300_1860 No 
pepV Dipeptidase M24.004 SAUSA300_1697 Yes 
pepZ Aminopeptidase M17 SAUSA300_0845 No 
* aAminopeptidases are assigned as putatively cleaving single, di, tri, or multiple (oligo) 
amino acids from protein and peptide substrates based on homology analysis. 
bShown are families for each aminopeptidase enzyme, classified based on putative 
amino acid specificity and the necessity of metal cofactors, from by the MEROPS 
peptidase database 
cGene annotation from the S. aureus USA300 genome 
dNotation as to whether the transposon insertion for relevant genes causes 
transcriptional defects in genes located downstream (determined herein by qPCR) 
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possible polar effects caused by the transposon insertions (Figure 2 A-K). This was 
done in order to ensure any phenotypes seen were not due to transcriptional defects in 
genes downstream of the transposons. From this comparison, six mutations (pepA2, 
pepA3, pepF1, pepF2, pepP1, and pepT1) were determined to be nonpolar (Figure 2 A-
F), while five mutations (pepA1, pepP2 pepT2 pepV, and pepS) were determined 
putatively polar (Figure 2 G-K). Of the non-polar insertions, pepA2, pepA3, pepF2 and 
pepP1 were all deemed to be monocistronic; whilst pepF1 appears to be the second 
gene in a two-gene operon; and pepT1 is the third gene in a three-gene operon. For the 
putatively polar insertions, pepA1 is located upstream of several genes in a large 
operon, pepP2, pepT2 and pepV are each the upstream gene of separate two gene 
operons, and pepS is the second gene in a three gene operon (Fig. 2K). Interestingly, 
the gene downstream of pepT2 is gnd, which encodes for 6-phosphogluconate 
dehydrogenase, an essential protein in S. aureus (138, 155). As such, it appears 
unlikely that the pepT2 insertion could be polar. To determine if this is in fact the case, 
real time PCR analysis was performed to determine which, if any, of the putatively polar 
mutations cause effects of their neighboring, downstream genes. For this analysis, 
genes showing no fold change in transcript for the mutant strain versus the wild-type 
were determined to be non-polar, whilst those showing significant deviation (increased 
or decreased) compared to the parent were considered polar.  The gene downstream of 
pepA1 (SAUSA300_1690) was identified as having a 1.6-fold decrease in transcript for 
the mutant strain versus the wild-type (Fig. 3A). Although the fold change pepA1 is not 
considered significant by student’s t-test, the potential for problems was deemed too 
large to risk, and the insertion was thus determined to be polar. The gene downstream  
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Figure 2. RNA Sequence Analysis of Aminopeptidase Operon Structure in S. 
aureus. Shown are the eleven aminopeptidase genes taken from CLC Genomics 
Workbench analysis of S. aureus USA300 Hou RNAseq using exponentially growing 
cultures (139). Genes are represented as arrows according to the direction of their 
transcript, and gene names are indicated in bold. The red and green lines represent 
RNA sequence reads. Green reads map to the positive sense strand, while red reads 
map to the antisense strand. Genes putatively located in an operon are grouped by a 
thick black line.  
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of pepP2 (SAUSA300_1490) was identified as having a negligible 0.8-fold increase in 
transcript in the mutant strain, indicating this is a nonpolar insertion (Fig. 3B). Similarly, 
the gene downstream of pepT2 (SAUSA300_1459) also had a marginal 0.8-fold 
increase in transcript for the mutant, and was determined to be nonpolar (Fig. 3C). 
Finally, the gene downstream of pepV (SAUSA300_1696) was identified as having a 8-
fold decrease in transcript for the mutant strain, making this mutation strongly polar (Fig. 
3D). Prior to the completion of this work, a silent, non-polar mutant for pepS was 
constructed by others in the lab; thus abrogating the need to assess this mutant.  
 
Growth Analysis of the Remaining Non-Essential S. aureus Aminopeptidase 
Mutants. Typically, aminopeptidases are believed to play a role in nutrition and 
metabolism, by liberating amino acids from peptides imported into the cell (119). 
Interestingly, the previously characterized LAP/pepZ mutant was not found to have any 
defects in growth for any media tested (130). To explore the impact of disrupting the 
remaining, non-essential aminopeptidases, we first determined the ability of the S. 
aureus aminopeptidase mutants to grow in TSB, a nutrient rich media. Exponentially 
growing USA300 Houston wild-type strain, as well as each of the eleven 
aminopeptidase mutant strains were separately inoculated into TSB, in triplicate, at a 
starting optical density (OD600) of 0.05, and allowed to grow for 6h at 37°C with shaking. 
In order to determine cell growth, samples were taken every hour and their ODs were 
measured. We found that none of the aminopeptidase mutant strains showed 
differences in growth as compared to the wild-type strain (Fig. 4), including for 
ampS/pepS, a mutation in which was previously identified in an anti-sense mutagenesis  
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Figure 3. Quantitative Real-Time PCR Analysis to Determine Polarity of NTML 
Insertions. Quantitative real time PCR analysis was performed for the genes 
immediately downstream of aminopeptidase transposon insertions to assess polarity. 
Shown is data from the USA300 Houston wild-type compared to the denoted mutant 
strain. The 16S rRNA gene was used as an internal control, as described in the 
methods. The downstream genes were pepA1 (SAUSA300_1690), pepP2 
(SAUSA300_1490), pepT2 (gnd), and pepV (SAUSA300_1696). All experiments were 
performed in triplicate. Significance was determined using a student’s t-test (****, p < 
0.0001), error bars shown ±SEM.  
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screen (154), as resulting in a growth defect. As such, in our study, it appears that all 
eleven aminopeptidase enzymes are dispensable for growth in TSB. 
 
In several Lactobacillus species, aminopeptidase enzymes are necessary to allow the 
organism to exploit protein-rich environments in order to survive (156). Exogenous 
proteins are first broken down by extracellular proteases, and the resulting peptides are 
imported into the cell and N-terminally cleaved by aminopeptidases; this process 
releases free amino acid constituents which can then be utilized in metabolic pathways 
(119). In order to determine if the PepT1 and PepT2 enzymes are necessary for the 
degradation of peptides for metabolism, we assayed their ability to grow in a peptide-
rich environment.  Exponentially growing wild-type cells, as well as those for each of the 
eleven aminopeptidase mutant strains, were separately inoculated, in triplicate, into 
10% skim milk at a starting OD600 of 0.05, and allowed to grow for 24h at 37°C with 
shaking. Samples were taken every hour, and serially diluted, before plating, in 
duplicate, onto tryptic soy agar (TSA) to assess cell viability by CFU/mL. Surprisingly, 
there were no differences in growth between the aminopeptidase mutant strains and the 
wild-type (Fig. 5). These results demonstrate that the eleven S. aureus aminopeptidase 
enzymes are not essential in the utilization of peptides during growth, suggesting that 
they may have a role beyond nutrition in S. aureus, similar to that which we have 
previously hypothesized for PepZ (130).  
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Figure 4. S. aureus Aminopeptidases Are Not Required for Growth in TSB. 
Exponentially growing wild-type, and aminopeptidase mutant strains were separately 
inoculated, in triplicate, into TSB at a starting OD of 0.05. Samples were taken every 
hour for 6 h, and measured for OD600. Error bars are shown ±SEM.  
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Figure 5. S. aureus Aminopeptidases Are Not Necessary for Growth in Peptide 
Rich Media. Exponentially growing wild-type, and aminopeptidase mutant strains were 
separately inoculated, in triplicate, into 10% skim milk at a starting OD of 0.05, and 
grown for 24 h at 37°C with shaking. Samples were taken every hour, and cell viability 
assessed by calculating CFU/mL. Error bars are shown ±SEM.  
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The Influence of S. aureus Aminopeptidases on Virulence. Previously, our lab has 
characterized LAP/pepZ, a leucine aminopeptidase that is necessary for virulence in S. 
aureus (131). Given the lack of function in nutrition, we explored whether the other 
eleven uncharacterized aminopeptidases in S. aureus potentially have a role in 
pathogenesis. To investigate this, we assessed the ability of the aminopeptidase 
mutants to survive and propagate in whole human blood. Exponentially growing wild-
type and aminopeptidase mutant cells were separately inoculated into whole human 
blood, and incubated for 4h at 37°C with shaking. Samples were withdrawn after 4h, 
and plated on TSA to determine percent recovery compared to the inocula. Of note, 
nine of the aminopeptidase mutants showed no significant difference compared to wild-
type strain in these tests (Fig. 6A-D). Interestingly, however, pepF2 demonstrated a 1.7-
fold decrease in survival compared to the inoculum (Fig. 6B). More striking was the 
observation that both M20 family enzymes (pepT1 and pepT2) displayed significant 
defects in survival after 4h in human blood, as compared to the wild-type strain (Fig. 
6C). Specifically, we noted a 2-fold decrease for the pepT1 mutant, and even more 
pronounced 3.1-fold decrease for the pepT2 mutant.  
 
The S. aureus pepT1 and pepT2 Enzymes Are Required for Disease Causation 
During Systemic Infection. Given the importance of both pepT1 and pepT2 to survival 
in human blood, we next set out to assess their role in disease using a systemic model 
of murine co-infection. As such, 10 mice were co-infected intravenously with a total of 5 
x 10! CFU/mL of the wild-type and either the pepT1 or pepT2 mutant strains in a 1:1 
ratio. The infection was allowed to progress for 7 days before the mice were 
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Figure 6. Survival of S. aureus Aminopeptidase Mutants in Whole Human Blood. 
Exponentially growing wild-type and aminopeptidase mutant strains were separately 
inoculated, in triplicate, into whole human blood. Samples were taken after 4 h, and the 
percent survival calculated by CFU/mL compared to the inoculum. Significance was 
determined using a student’s t-test ( * ,p < 0.05; ***, p < 0.005); error bars are shown 
±SEM.  
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subsequently euthanized. The kidneys, brain, heart, liver, lungs, and spleen were 
harvested, homogenized, serially diluted, and plated in duplicate on TSA and TSA 
containing erythromycin. The pepT1 and pepT2 mutant strains were differentiated from 
wild-type by selecting for the erythromycin resistance cassette in the transposon 
insertions. The bacterial burden in each organ was then quantified by calculating 
CFU/mL for the WT and mutant strains. One mouse co-infected with wild-type and 
pepT1 mutant strains died during the 7 day infection period and was omitted from the 
study, however all mice in the pepT2 mutant co-infection survived.  
 
Interestingly, both pepT1 and pepT2 mutants displayed a strikingly decreased ability to 
cause septic infection. For the pepT1 mutant, we noted significantly diminished mutant 
cell accumulation in all organs apart from the liver. The most notable of these was in the 
brain, where we observed only 4.8% of the total bacterial population resulting from the 
pepT1 mutant strain and 95.2% resulting from the wild-type, leading to an approximately 
20.8-fold decrease in mutant cells from the inoculum (Fig. 7A). In the lungs, we 
observed 14.2% of the total bacterial population resulting from the mutant strain and 
85.8% resulting from the parental strain, which correlates to an approximate 7-fold 
decrease in mutant cells from the inoculum (Fig. 7B). In the heart, 17.3% of the cells 
recovered were from the pepT1 mutant bacteria while 82.7% were from the wild-type, 
resulting in a 5.7-fold decrease in accumulation of mutant cells as compared to the total 
bacterial population (Fig. 7C). In the kidneys, pepT1 mutant cells accounted for only 
20.7% of the total bacteria recovered while 79.3% of cells were wild-type, leading to a 
4.8-fold decrease in mutant cells from the inoculum (Fig. 7D). In the spleen, we 
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observed only 23.2% of the total bacterial population resulting from the mutant strain 
while 76.8% of cells were from the parental strain, leading to a 4.3-fold decrease in 
accumulation of mutant cells from the inoculum (Fig. 7E). In the liver, we observed 
34.3% of the total bacterial population resulting from the mutant strain and 65.7% 
resulting from the wild-type strain (Fig. 7F). Although this is not significant by student’s t-
test, a notable 2.9-fold decrease was observed in mutant cell accumulation from the 
inoculum.  
 
For the pepT2 mutant, we noted significantly diminished mutant cell accumulation in all 
organs. The most prominent of which was the brain, where only 11.7% of the total 
bacterial population resulted from the mutant strain and 88.3% from the parental strain, 
correlating to a 8.5-fold decrease in accumulation of mutant cells from the inoculum 
(Fig. 8A). In the heart, we observed only 17.6% of the total bacterial burden consisting 
of mutant cells while 82.4% consisted of wild-type cells, leading to a 5.6-fold change 
decrease of pepT2 mutant cells from the total bacterial population (Fig. 8B). In the 
kidneys, we observed 21% of the bacterial population resulting from the mutant strain 
and 79% from the wild-type, correlating to a 4.7-fold decrease in accumulation of mutant 
cells from the total inoculum (Fig. 8C). In the lungs, pepT2 cells accounted for only 
23.4% of the total bacteria recovered while 76.6% were wild-type, leading to a 4.2-fold 
decrease in mutant cells from the total bacterial burden (Fig. 8D). In the spleen, we 
observed only 29% of the total bacterial populating resulting from the mutant strain 
while 71% were of the wild-type strain, correlating to a 3.4-fold decrease in 
accumulation of mutant cells from the inoculum (Fig. 8E). Finally, in the liver, we  
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Figure 7. The S. aureus pepT1 Enzyme Is Required for Disease Causation in 
Murine Models of Infection. Mice were co-infected with 5 x 107 CFU/mL of the wild-
type and pepT1 mutant strains in a 1:1 ratio. The infection was allowed to progress for 7 
days and the mice were subsequently euthanized. The bacterial percent recovery was 
quantified from the brain (A), lungs (B), heart (C), kidneys (D), spleen (E), and liver (F). 
The data is represented as box-and-whisker plots. Percent recovery was determined 
using median values represented as a black line in the center of the box. Significance 
was determined using a student’s t-test ( **, p < 0.005; ***, p < 0.0003; ****, p < 0.0001). 
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observed only 32.6% of the total bacterial load consisting of mutant cells while 67.4% 
were of the parental strain, leading to an approximate 3-fold decrease in bacterial load 
of the mutant from the total inoculum (Fig. 8F). These results establish the 
indispensability of both the PepT1 and PepT2 enzyme in full S. aureus virulence. 
 
Given the importance of both the pepT1 and pepT2 enzymes for disease causation in a 
systemic model of co-infection, we next set out to assess the ability of a pepT1/T2 
mutant to cause infection. As such, a pepT1/pepT2 double mutant was constructed, and 
10 mice were co-infected intravenously as described for the single mutants above. 
Interestingly, after 7 days, the pepT1/T2 mutant displayed an extraordinarily reduced 
ability to cause septic infection. We observed significantly diminished mutant cell 
accumulation in all organs, most notably in the heart, where we observed less than 1% 
of the total bacterial burden consisting of mutant cells, and 99.37% consisting of wild-
type cells, resulting in a 158.7-fold decrease in the amount of mutant bacteria recovered 
compared to the total inoculum (Fig. 9A). In the brain, we observed 4.1% of the total 
bacterial population resulting from the mutant strain and 95.9% resulting from the 
parental strain, correlating to a 24.3-fold decrease in accumulation of mutant cells from 
the inoculum (Fig. 9B). In the spleen, only 5.5% of the total cells recovered were from 
the pepT1/T2 mutant bacteria, while 94.5% were wild-type, resulting in a 18-fold 
decrease in accumulation of mutant cells from the total bacterial population (Fig. 9C). In 
the lungs, we observed only 5.5% of the total bacterial population resulting from the 
mutant strain, while 94.5% resulted of the parental strain, correlating to a 18-fold 
decrease in accumulation of mutant cells from the inoculum (Fig. 9D). In the liver,  
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Figure 8. The S. aureus pepT2 Enzyme Is Required for Disease Causation in 
Murine Models of Infection. Mice were co-infected with 5 x 107 CFU/mL of the wild-
type and pepT2 mutant strains in a 1:1 ratio. The infection was allowed to progress for 7 
days and the mice were subsequently euthanized. The bacterial percent recovery was 
quantified from the brain (A), heart (B), kidneys (C), lungs (D), spleen (E), and liver (F). 
The data is represented as box-and-whisker plots. Percent recovery was determined 
using median values represented as a black line in the center of the box. Significance 
was determined using a student’s t-test ( ***, p < 0.007; ****, p < 0.0001). 
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pepT1/T2 mutant cells accounted for only 6.8% of the total bacteria recovered, while 
93.2% were of the wild-type strain, resulting in a 14.7-fold decrease in mutant bacterial 
load compared to the total inoculum (Fig. 9E). In the kidneys, we observed only 11.3% 
of the total bacterial population resulting from the mutant strain, while 88.7% were from 
the wild-type strain, resulting in a 8.8-fold decrease of mutant cells from the inoculum 
(Fig. 9F).  
 
To assess our results overall, we compared the percent recovery of the pepT1, pepT2, 
and pepT1/T2 mutants as compared to the wild-type from our murine models of co-
infection (Fig. 10). Interestingly, in the brain, the percent recovery of the pepT1 and 
pepT1/T2 double mutant bacteria is nearly the same, while the percent recovery from 
the pepT2 mutant is much higher. These results suggest the absence of the PepT1 
enzyme is likely the predominant factor driving the diminished mutant accumulation 
phenotype seen in the brain. In the heart, liver, lungs, and spleen, the pepT double 
mutant has a much lower percent recovery than the pepT1 and pepT2 single mutants 
combined. These results indicate that during the single mutant models of co-infection, 
the phenotype ensuing from the loss of the PepT1 or PepT2 enzyme in these organs is 
being partly masked by the presence of the other enzyme. In the kidneys, the percent 
recovery of the pepT1/pepT2 double mutant is approximately half of the percent 
recovery seen from either the pepT single mutants, suggesting both enzymes are 
equally necessary to mount a successful infection.  
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Figure 9. Both S. aureus pepT Enzymes Are Required to Cause Disease in Murine 
Models of Infection. Mice were co-infected with 5 x 107 CFU/mL of the wild-type and 
pepT1/T2 double mutant strains in a 1:1 ratio. The infection was allowed to progress for 
7 days and the mice were subsequently euthanized. The bacterial percent recovery was 
quantified from the heart (A), brain (B), spleen (C), lungs (D), liver (E), and kidneys (F). 
The data is represented as box-and-whisker plots. Percent recovery was determined 
using median values represented as a black line in the center of the box. Significance 
was determined using a student’s t-test ( ****, p < 0.0001). 
 
WT pepT1/T2
0
20
40
60
80
100
%
 C
el
ls
 R
ec
ov
er
ed
 H
ea
rt
  
****
WT pepT1/T2
0
20
40
60
80
100
%
 C
el
ls
 R
ec
ov
er
ed
 B
ra
in
****
WT pepT1/T2
0
20
40
60
80
100
%
 C
el
ls
 R
ec
ov
er
ed
 S
pl
ee
n
****
WT pepT1/T2
0
20
40
60
80
100
%
 C
el
ls
 R
ec
ov
er
ed
 L
un
gs
****
WT pepT1/T2
0
20
40
60
80
100
%
 C
el
ls
 R
ec
ov
er
ed
 K
id
ne
ys
****
WT pepT1/T2
0
20
40
60
80
100
%
  C
el
ls
 R
ec
ov
er
ed
 L
iv
er
****
A 
F E 
D C 
B 
69 
 
Figure 10. Comparison of Percent Recovery of Single and Double pepT Enzyme 
Mutants in Murine Models of Infection. Percent recovery comparison of the pepT1, 
pepT2, and pepT1/T2 double mutant relative to the wild-type in murine models of co-
infection.  
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Investigating the Role of PepT1 and PepT2 in ex vivo Models of Human Infection. 
In order to assess how the pepT1/pepT2 double mutant survives and propagates in 
whole human blood compared to the other aminopeptidase mutants, exponentially 
growing wild-type, pepT1, pepT2, pepT1/T2 mutant, as well as their respective pepT1 
and pepT2 complement strains, were separately inoculated into whole human blood, 
and incubated for 4h at 37°C with shaking. Samples were withdrawn after 4h, and 
plated on TSA to determine percent recovery compared to the inocula. As observed 
before, both M20 family single enzyme (pepT1 and pepT2) mutants demonstrated 
significantly decreased ability to survive and propagate in whole human blood after 4h, 
as compared to the wild-type strain (Fig. 11). Specifically, we noted a 4.1-fold decrease 
for the pepT1 mutant, and a 2.5-fold decrease for the pepT2 mutant. In addition, the 
pepT1 and pepT2 complement strains show no difference in survival compared to the 
parental strain, suggesting the respective phenotypes are a result of the absence of the 
pepT1 and pepT2 enzymes.  Of interest, we observed a striking 14-fold decrease in 
percent survival for the pepT1/pepT2 mutant compared to the parental strain. Because 
the fold change in percent survival for the pepT double mutant is much lower than the 
pepT single mutants combined, these results suggest that the phenotypic effects from 
the loss of either PepT1 or PepT2 is strongly additive, and that in the single mutants this 
is being counteracted by the presence of the other enzyme, similar to that which we 
observed in the heart, liver, lungs, and spleen during systemic models of co-infection.  
 
To explore the blood survival defect further, we next sought to investigate the role of 
these enzymes during interaction with host immune cells. As such, immortalized THP-1 
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Figure 11. Survival Analysis of pepT Mutant Strains in Whole Human Blood. 
Exponentially growing wild-type, pepT1, pepT2, pepT1/pepT2 double mutant, as well as 
pepT1 and pepT2 complement strains were separately inoculated, in triplicate, into 
whole human blood. Samples were taken after 4 h, and the percent survival calculated 
by CFU/mL compared to the inoculum. Significance was determined using a student’s t-
test ( * ,p < 0.05; **, p < 0.005), error bars are shown ±SEM.  
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human macrophage-like cells were separately infected with 106 CFU/mL of the wild-
type, pepT1, pepT2, and pepT1/T2 mutant bacteria. Phagocytosis was allowed to 
progress for 1h at 37°C with 5% CO2, and then gentamicin was added to kill any 
extracellular bacteria. The macrophages were subsequently lysed, and intracellular 
bacterial loads were serially diluted and plated on TSA to determine percent 
phagocytized compared to inocula. Upon analysis, we determined that 26.7% of the 
wild-type bacteria infected were phagocytized (Fig. 12A). In contrast, both the pepT1 
and pepT2 mutants showed decreased ability to evade phagocytosis. Specifically, 
nearly 50% of the total pepT1 mutant bacteria infected were phagocytized, 
corresponding to a 1.8-fold increase in mutant cells as compared to wild-type. In 
addition, 60% of the total pepT2 bacteria were phagocytized, corresponding to a 2.2-
fold increase in mutant cells as compared to wild-type. Interestingly, the pepT1/T2 
mutant displayed enhanced phagocytosis at levels comparable to the single mutants 
(60% cells phagocytized, 2.2-fold increase). These results indicate that both the PepT1 
and PepT2 enzymes are needed together in order to successfully evade phagocytosis, 
and that loss of both is not additive to the phenotype.  
 
To assess the ability of the mutants to survive inside host immune cells, the 
phagocytosis assay was performed again in an identical manner; however, we allowed 
them to proceed for 24h. When the percent survival of the wild-type was studied, we 
determined that 4.3% of the total bacteria phagocytized survived (Fig. 12B). Importantly, 
after this time only 2.4% of the total pepT1 mutant bacteria phagocytized were found to 
have survived, correlating to a 1.8-fold decrease as compared to the wild-type. For the 
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pepT2 mutant we noted 1.5% of the total cells phagocytized were recovered, which 
correlates to a 3-fold decrease as compared to wild-type.  Of special interest, 1.3% of 
the pepT1/T2 mutant bacteria were able to survive after 24h, displaying a 3.3-fold 
decrease as compared to wild-type. Once again, the pepT double mutant showed 
decreased survival at levels comparable to the single mutants. Thus it would appear 
that the presence of both the PepT1 and PepT2 enzymes together is necessary for 
survival inside host immune cells, and suggests that in this environment, the function of 
one enzyme is masked by the other.  
 
The Defect in pepT1 and pepT2 Mutant Strain Pathogenesis is Not Mediated by 
Impaired Synthesis of Virulence Factors. In order to determine if the virulence 
phenotypes seen for the pepT mutants are facilitated by altered production of virulence 
factors, wild-type, pepT1, pepT2, and pepT1/T2 double mutant strains were inoculated 
onto TSA, blood agar (hemolytic activity), casein agar (protease activity), as well as 
nuclease agar (nuclease activity), to examine deficits in virulence factor production. An 
agr mutant strain was included as a control, due to its lack of hemolytic and proteolytic 
activity. No differences in growth on TSA (a nutrient rich agar) were seen for any of the 
mutant strains as compared to wild-type (Fig. 13A).  There were also no differences in 
hemolytic activity, protease activity, or nuclease activity seen for the mutant strains as 
well (Fig. 13B-D), suggesting these enzymes do not influence the activity of key 
virulence factors.  
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Figure 12. The pepT Mutants Have a Decreased Ability to Evade and Survive 
Inside Human Immune Cells. THP-1 human macrophage-like cells were separately 
infected with wild-type, pepT1, pepT2, and pepT1/T2 double mutant strains, in triplicate. 
(A): Phagocytosis was allowed to proceed for 1 h, and the percent cells phagocytized 
calculated by CFU/mL compared to inoculum. (B) Phagocytosis assay was allowed to 
proceed for 24 h, and the intracellular percent survival was calculated by CFU/mL 
compared to CFU/mL phagocytized. Significance was determined using a student’s t-
test ( * ,p < 0.05; **, p < 0.005), error bars are shown ±SEM.  
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Figure 13. The Avirulent Phenotype of the pepT Single and Double Mutants Is Not 
Associated with Altered Production of Virulence Factors. Wild-type, pepT1, pepT2, 
pepT1/T2 and agr mutant strains were inoculated onto TSA (A), sheep blood agar (B), 
casein nutrient agar (C), and nuclease agar (D), to determine key virulence factor 
activity.  
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To further quantify potential hemolytic activity, culture supernatants from the wild-type,  
pepT1, pepT2 and pepT1/pepT2 mutant strains were separately inoculated, in triplicate, 
into whole human blood and incubated at 37oC for 40 minutes. The OD543 of resulting 
supernatants was then assessed as a measure of hemolytic activity; with untreated 
samples used as a control. As expected, none of the mutant strains displayed any 
differences in hemolysis as compared to the parental strain (Fig. 14). These results 
strongly indicate the decreased infection observed for mutant strains is not the result of 
altered production of virulence factors.  
 
Assessing the Role of PepT1 and PepT2 in Biofilm Formation. Many of the 
diseases caused by S. aureus are associated with the formation of a biofilm within the 
host (157-159). Essentially, a biofilm is a microbial community embedded in a self-
produced extracellular matrix that is semi-permanently attached to host tissues (160). 
As previously described, proteases have been shown to play several roles in the 
modulation of S. aureus biofilm formation and dispersal. As such, we wanted to explore 
the impact of PepT1, and PepT2 on biofilm formation using ex-vivo models of biofilm 
attachment. Overnight cultures of wild-type, SH1000, 8325-4, pepT1, pepT1 
complement, pepT2, pepT2 complement, pepT1/T2, were separately grown, in 
triplicate. The S. aureus SH1000 strain was used as a positive control, and the S. 
aureus 8325-4 strain was used as a negative control. Cultures were then added to a 96-
well microtiter plate containing 20% human plasma, and incubated at 37oC for 24 hours. 
Biofilms were then fixed with 100% ethanol, and stained with crystal violet. Biofilm 
growth was quantified by measuring absorbance levels of the eluted crystal violet. Of 
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Figure 14. The PepT1 and PepT2 Enzymes Do Not Influence Hemolysis Activity. 
Culture supernatants from the wild-type, pepT1, pepT2, and pepT1/T2 mutant strains 
were separately inoculated, in triplicate, into whole human blood and incubated at 37oC 
for 40 minutes. Hemolytic activity was assessed by measuring the OD543 of resulting 
supernatants. Untreated samples were used as a control. Hemolysin units were 
determined using the formula (OD543 x 100) / (mL supernatant) x (min) x OD600. Error 
bars are shown ±SEM.  
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note, none of the mutants tested displayed any significant decreases in biofilm 
formation as compared to wild-type strain (Fig 15). These results suggest that the 
PepT1 and PepT2 enzymes minimally contribute to S. aureus biofilm formation.  
 
Cellular Localization of PepT1 and PepT2. Despite no evidence of a signal sequence 
in either of the PepT enzymes, we next explored their cellular localization. This is of 
importance, because if these enzymes were secreted, it would readily explain their 
apparent role in virulence. As such, we utilized pMK4 plasmid shuttle vectors, which 
were separately constructed and contained the pepT1 and pepT2 genes bearing a C-
terminal 6-histidine tag. Cytoplasmic, membrane, and secreted protein fractions were 
obtained from USA300 wild-types harboring these plasmids after 15h growth, and 
subjected to Western blot, using an anti-His6 antibody. Upon analysis, both the PepT1 
and PepT2 enzymes were concluded to be located intracellularly (Fig. 16) with no 
evidence of either seen in the membrane or secreted protein fractions. To determine the 
cellular amounts of PepT1 and PepT2, we performed Western blot analysis as 
previously described at various intervals during growth, including 3h, 6h, 9h, and 24h. 
Both the PepT1 and PepT2 enzymes were seemingly produced at equivalent levels 
during each time point (Fig. 17).  
 
Growth Analysis of the pepT1/pepT2 Double Mutant. Although neither the pepT1 or 
pepT2 single mutants displayed any growth defects in TSB, we next set out to explore 
whether the absence of both enzymes would have any effects on growth. Importantly, 
the pepT1/pepT2 mutant strain displayed no differences in growth as compared to the  
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Figure 15. The S. aureus pepT Enzyme Mutants Are Not Required for ex vivo 
Biofilm Formation. Overnight cultures of wild-type, SH1000, 8325-4, pepT1, pepT1 
complement, pepT1, pepT2 complement, and pepT1/T2 mutant strains were separately 
grown, in triplicate, in biofilm media, and then incubated with 20% human plasma at 
37oC for 24 h in a 96-well microtiter plate. Biofilms were fixed with 100% ethanol 
followed by staining with crystal violet. Biofilm growth was calculated by measuring the 
OD595 of the crystal violet elution. Significance was determined using a student’s t-test ( 
* ,p < 0.05), error bars are shown ±SEM.  
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Figure 16. PepT1 and PepT2 Are Intracellular Enzymes. pMK4 plasmid vectors 
encoding histidine tagged forms of the PepT1 and PepT2 enzymes were transduced 
into the respective USA300 Houston background. The cytoplasmic, membrane, and 
secreted protein fractions were obtained after 15h growth, and are shown. An empty 
pMK4 vector was used as a control (EV). Molecular weight markers are indicated, in 
kDa.  
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Figure 17. PepT1 and PepT2 Are Produced Constitutively during Growth. 
Cytoplasmic protein fractions are shown at time points 3 h (lanes 1, 5, and 9), 6 h (lanes 
2, 6, and 10), 9 h (lanes 3, 7, and 11), and 24 h (lanes 4, 8, and 12). An empty vector 
was used as a control (EV). Molecular weight markers are indicated, in kDa.  
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wild-type strain (Fig. 18). Next, to assess the ability of the pepT1/pepT2 mutant to 
proliferate in a peptide rich environment, the pepT1/T2 mutant strain was inoculated into 
10% skim milk and allowed to grow for 24h. Again we observed no differences in growth 
between the double mutant strain as compared to the wild-type (Fig. 19).  
 
Analysis of the pepT1 and pepT2 Mutants in Response to Oxidative Stress. During 
an ex vivo model of human infection, we determined our pepT1 and pepT2 gene 
mutants to have increased sensitivity towards phagocytosis and killing by THP-1 
macrophages. Importantly, oxidative stress via reactive oxygen species (ROS) is a 
critical method by which phagocytes damage and kill bacteria (161). Therefore, we 
wanted to examine the ability of the pepT1 and pepT2 mutant strains to survive 
exposure to oxidative stress. As such, exponentially growing wild-type, pepT1, and 
pepT2 mutant strains were subjected to the addition of 150mM H2O2. No differences in 
percent survival were seen for either the pepT1 or pepT2 mutants as compared to the 
wild-type strain, after H2O2 exposure (Fig. 20), suggesting these enzymes are not 
essential in response to oxidative stressors.  
 
Phenotypic Analysis of the pepT Single and Double Mutants to Explore Further 
the Avirulent Phenotype. We next sought to derive explanation for the avirulence 
phenotype of the pepT mutant strains using a battery of phenotype analyses. Firstly, we 
grew the mutant strains in amino acid limiting media. Cultures were allowed to grow for 
7 days at 37oC static, as well as with shaking. We found neither the pepT1 nor pepT2 
mutant to have differences in growth compared to the wild-type (Fig. A-1). Next  
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Figure 18. The pepT1/T2 Double Mutant Does Not Display A Growth Defect in 
TSB. Exponentially growing wild-type, and pepT1/T2 double mutant strains were 
separately inoculated, in triplicate, into TSB at a starting OD of 0.05. Samples were 
taken hourly for 6 h, and measured for OD600. Error bars are shown ±SEM.  
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Figure 19. The M20 Family Enzymes, PepT1 and PepT2, Are Not Necessary for 
Growth in  Peptide Rich Media. Exponentially growing wild-type, and pepT1/pepT2 
double mutant strains were separately inoculated, in triplicate, into 10% skim milk at a 
starting OD of 0.05, and grown for 24 h at 37°C with shaking. Samples were taken 
every hour, and cell viability assessed by calculating CFU/mL. Error bars are shown 
±SEM.  
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Figure 20. The pepT1 and pepT2 Mutants Are Not Involved in Oxidative Stress 
Response. Exponentially growing wild-type, pepT1, and pepT2 mutants were exposed, 
in triplicate, to 150mM H2O2 for 10 minutes at room temperature. Samples were taken at 
0, 5, and 10 minutes, serially diluted, and plated in duplicate on TSA. Percent survival 
was determined by calculating CFU/mL compared to the inoculum. Error bars are 
shown ±SEM.  
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we used toluene and oleic acid to assess membrane integrity. We again found no 
differences in membrane integrity for the pepT1 or pepT2 mutant as compared to the 
parental strain, when subjected to either toluene (Fig. A-2A), or oleic acid (Fig. A-2B). In 
order to better understand the role of the PepT1 and PepT2 enzymes in membrane 
disruption and autolysis, we sought to assess the response of our wild-type, and 
pepT1/T2 strains to a the detergent, Triton X-100. As such, a Triton X-100 induced 
autolysis assay was performed. Again, we observed no notable defects in survivability 
for any strain (Fig. A-3).  
 
It has been previously shown that expression of a PepT homologue in Salmonella 
typhimurium is induced by anaerobiosis (162, 163). In order to explore the role of the 
PepT1 and PepT2 enzymes in anaerobic growth, exponentially growing wild-type, 
pepT1, pepT2, and pepT1/T2 mutant strains were separately inoculated, in triplicate, in 
TSB, and allowed to grow for 24h anaerobically. Cultures were then grown in two 
conditions: 37oC with shaking, or well as 37oC statically. We found neither the pepT1, 
pepT2, nor pepT1/T2 mutants to have differences in percent survival when grown 
anaerobically, both at 37oC with shaking (Fig. A-4A), and at 37oC statically (Fig. A-4B). 
These results suggest the PepT1 and PepT2 enzymes are not necessary to growth 
under anaerobic conditions. The response of the pepT1 and pepT2 mutants to 
anaerobic conditions was also assessed using specialty media. The experiment was 
performed using TSA, sheep blood agar, casein nutrient agar, nuclease agar, amino 
acid limiting media, as well as mannitol salt agar (MSA). Plates were separately 
inoculated using three isolated bacterial colonies from the respective wild-type, pepT1, 
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pepT2, pepT1/T2 mutant strains, and grown in parallel under both aerobic and 
anaerobic conditions at 37oC overnight. We found no growth impairment of any strain, 
as compared to wild-type for each growth media (results not shown).  
 
In order to further investigate the response of pepT1, pepT2, and pepT1/T2 to external 
stimuli, we set out to determine whether exposure to various chemical stressor 
compounds would alter cellular survival as compared to the parental strain. This was 
achieved by performing disk diffusion assays to expose the wild-type, pepT1, pepT2, 
and pepT1/T2 mutant strains to a wealth of chemical stressor compounds (Table 3). As 
such, TSA agar plates were overlaid with 5 mL of 0.07% top agar containing the wild-
type, pepT1, pepT2, or pepT1/T2 mutant strains at a 1:1000 dilution. Chemical 
stressors were subsequently applied in 10µl volumes to 7mm round sterile Whatman 
Paper filter disks, which were placed, in triplicate, on the top agar. Plates were 
incubated for 24h at 37oC and screened for differences in susceptibility as compared to 
the parental strain. Upon observation, we determined there to be no significant 
differences in susceptibility of the pepT1, pepT2, or pepT1/T2 mutants as compared to 
wild-type (data not shown).  
 
Transcriptional Profiling of the pepT1 and pepT2 Mutants During Growth. Previous 
Western blot data has demonstrated that the PepT1 and PepT2 enzymes appear to be 
constitutively produced by S. aureus cells. In order to understand how their production 
is mediated at the level of transcription, we created pepT1 and pepT2 lacZ reporter 
gene fusion strains. Strains were grown in TSB at 37oC with shaking, and samples were 
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taken every hour for 8h, and again at 24h. Samples were then measured for β-
galactosidase activity using 4-MUG as a substrate. Results for both strains show pepT1 
and pepT2 to have near identical expression patterns, with maximal transcription in TSB 
occurring 1h post-inoculation, followed by a steady decrease in expression throughout 
the remaining hours (Fig. 21). These results were slightly different than our previous 
Western blot data, which demonstrated that both the PepT1 and PepT2 enzymes were 
seemingly produced at equivalent levels during each time point of 3h, 6h, 9h, and 24h. 
 
We next sought to assess the effects of external stimuli on pepT1 and pepT2 
expression by exposure to our panel of chemical stressors (Table 3). TSA agar plates 
were overlaid with agar containing 3 µg/ml-1 of X-GAL, and either the pepT1-lacZ or 
pepT2-lacZ fusion strains at a 1:1000 dilution. Chemical stressors were subsequently 
applied to sterile filter disks, which were placed, onto the agar. Plates were incubated 
for 24h at 37oC and screened for the presence of blue halos around the perimeter of 
disks, which would result from cleavage of X-GAL by β-galactosidase (152), indicating 
induced expression. Interestingly, three chemicals were found to induce both pepT1 and 
pepT2 expression: phosphomycin, oxacillin, and penicillin-G, all of which disrupt 
bacterial cell wall synthesis (115, 164, 165). To assess transcriptional repression, the 
chemical stressor disk diffusion assays were performed as described above, with top 
agar containing 4 µg/ml-1 of X-GAL and either the pepT1-lacZ or pepT2-lacZ fusion 
strains at a 1:1000 dilution. Plate were incubated for 24h at 37oC and screened for the 
absence of blue halos, indicating the repression of transcription due to no X-GAL being 
cleaved by β-galactosidase. Upon observation, we determined there to be no significant  
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Figure 21. Maximal Transcription of pepT1 and pepT2 Occurs During Early 
Exponential Phase. USA300 strains containing the pepT1-lacZ or pepT2-lacZ reporter 
fusions, were separately grown, in triplicate, in TSB at 37oC with shaking for 24 h. 
Samples were taken every hour for 8 h and again at 24 h to measure β-galactosidase 
activity. Error bars are shown ±SEM.   
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repression of pepT1 or pepT2 transcription when exposed to the chemical stressor 
library.  
 
N-Terminomic Analysis to Ascertain Pathophysiological Targets of the PepT1 and 
PepT2 Aminopeptidases Within S. aureus Cells. Primarily, aminopeptidases are 
known to be involved in the turnover of exogenously imported proteins in order to aid in 
cellular nutrition (166). These important enzymes function by cleaving either single, or 
multiple amino acid residues from the N-terminus of proteins and peptides, and it’s 
these amino acid constituents that are then recycled for various cellular processes. 
Conversely, aminopeptidases can also play a role in protein bioactivation or inactivation 
cascades, by selectively cleaving residues of target proteins in order to form an active 
from of a relatively inactive precursor protein, and vice versa (119). In order to fully 
understand the precise mechanisms and pathways by which the PepT1 and PepT2 
aminopeptidase enzymes are employed in S. aureus, we sought to identify the exact 
substrate targets these proteins act upon. This was explored using N-terminomics, a 
cutting edge proteomics assay. N-terminomics is a high-content screen that can 
effectively identify protease substrate targets and their sites of cleavage by chemically 
tagging the alpha amine groups of the substrate targets post-proteolysis, enriching for 
the tagged N-termini, followed by identification and analysis of collected N-termini via 
Liquid Chromatography-Coupled Tandem Mass Spectrometry, LC-MS/MS (167-169). 
The LC-MS/MS data is then searched against a complete proteome in order to identify 
matching proteins and therefore, protease substrate targets.  
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To ascertain pathophysiological targets of the PepT1 and PepT2 enzymes within S. 
aureus, we performed the N-terminomics assay as previously described (167), see 
materials and methods. Our N-terminomic analysis identified 344 unique proteins 
across the wild-type, pepT1, and pepT2 mutant samples (Table A-1). Of these 344 
proteins identified, 214 were identified in each of the wild-type, pepT1, and pepT2 
mutant samples (Fig. 22), suggesting the intracellular proteome isolation and N-
terminomics methods we used were successful. In order to detect significant changes in 
N-terminal peptide abundance across the samples, a normalized T-Test of the total ion 
current (TIC) was performed against the total identified protein data-set with a 
significance level threshold of p <= 0.05. When compared to the wild-type, the pepT1 
mutant data-set identified 20 proteins showing significant changes in N-terminal peptide 
abundance (Table 5). More specifically, two proteins had an increase in abundance in 
the pepT1 mutant as compared to the parental strain: an uncharacterized protein with a 
157.2-fold increase in the mutant, and a 50S ribosomal protein L15 with a 3.39-fold 
increase in the mutant. Eleven proteins showed a significant decrease in abundance in 
the mutant strain as compared to the wild-type, corresponding to fold change decreases 
between 89.44 and 2.70. The remaining seven proteins showing substantial changes in 
N-terminal peptide abundance were only identified in the wild-type sample, and were 
thus absent from the pepT1 mutant.  
 
For the pepT2 mutant data-set, we identified 21 proteins showing significant changes in 
N-terminal peptide abundance as compared to the wild-type strain (Table 6). 
Specifically, three proteins had an increase in abundance in the pepT2 mutant as  
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Figure 22. Comparison of Protein Identifications from the N-Terminomic Analysis. 
Venn-Diagram comparison of the proteins identified during N-terminomic analysis of our 
wild-type (WT), pepT1 (T1), and pepT2 (T2) mutant strains. The center of the diagram 
and highlighted in yellow represents the 214 proteins identified from the 349 proteins in 
total which are found in each of the wild-type, pepT1, and pepT2 mutant strains. 
Overlapping circles represent data-sets with matching protein identifications.  
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Table 5. Wild-type and pepT1 N-Terminomics Analysis 
Identified Protein Accession # P-Value 
(p <= 0.05) 
Fold 
Change 
Quantitation 
Uncharacterized protein Q2FHC5_STAA3 0.037 157.22 Increase in T1 
50S ribosomal protein L15  RL15_STAA3 0.027 3.39 Increase in T1 
50S ribosomal protein L5  RL5_STAA3 0.041 89.44 Decrease in T1 
50S ribosomal protein L2  RL2_STAA3 0.0068 23.91 Decrease in T1 
Bifunctional purine biosynthesis 
protein PurH  PUR9_STAA3 0.0025 18.31 Decrease in T1 
Phosphate acetyltransferase  Q2FJ55_STAA3 0.047 16.53 Decrease in T1 
Glycine betaine/carnitine/choline 
ABC transporter  Q2FE52_STAA3 0.038 7.85 Decrease in T1 
Phosphoribosylformylglycinamidine 
synthase  Q2FI11_STAA3 0.045 6.31 Decrease in T1 
50S ribosomal protein L17  RL17_STAA3 0.016 5.95 Decrease in T1 
AANH-like and USP-like superfamily; 
universal stress protein Q2FG32_STAA3 0.012 5.81 Decrease in T1 
Chaperone protein DnaK  DNAK_STAA3 0.023 3.65 Decrease in T1 
2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase  ISPD_STAA3 0.042 2.74 Decrease in T1 
Uncharacterized protein  Q2FEN1_STAA3 0.037 2.70 Decrease in T1 
ATP-dependent Clp protease ATP-
binding subunit ClpC  CLPC_STAA3 0.008 N/A Found only in WT 
Pur operon repressor  Q2FJE6_STAA3 0.0049 N/A Found only in WT 
Uncharacterized protein  Q2FIV7_STAA3 0.031 N/A Found only in WT 
Dihydrofolate reductase  Q2FH12_STAA3 0.0031 N/A Found only in WT 	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Table 5. (Continued) 	  
50S ribosomal protein L16  RL16_STAA3 0.035 N/A Found only in WT 
Addiction System antitoxin 
(Txe/YoeB family) Q2FE41_STAA3 0.00037 N/A Found only in WT 
Phosphoglycerate kinase PGK_STAA3  0.030 N/A Found only in WT 
*Listed are the proteins identified in the wild-type/pepT1 N-terminomics analysis to have 
significant changes in N-terminal peptide abundance. Strains are abbreviated as 
follows: T1 – pepT1 mutant; WT – wild-type. A normalized T-Test of the TIC was 
performed against the total identified protein data-set with a significance level threshold 
of p <= 0.05. Quantitation profiles are indicated, representing a relative increase or 
decrease in peptide abundance as compared to the wild-type strain. 
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compared to the parental strain: two uncharacterized proteins with a fold change 
increase of 9.24 and 2.65, respectively, and a cytidine deaminase, with a 1.8-fold 
increase. Fourteen proteins showed a significant decrease in abundance in the mutant 
strain as compared to the wild-type, corresponding to fold change decreases between 
9.92 and 1.74. Of those fourteen proteins, one in particular, ArlR, is a response 
regulator of the arlRS two-component system, and has been previously shown to affect 
autolysis, capsule production, the production of numerous exoproteins, and is involved 
in the regulation of several virulence genes in S. aureus (86, 170, 171). The remaining 
four proteins showing substantial changes in N-terminal peptide abundance were only 
identified in the wild-type sample, and were thus absent from the pepT2 mutant. 
Interestingly, nearly one-third of the proteins showing significant differences in N-
terminal peptide abundance from both the pepT1 vs. wild-type, and pepT2 vs. wild-type 
N-terminomics analysis, were ribosomal proteins.  
 
Remarkably, seven proteins were identified in both the pepT1 and pepT2 mutants to 
have a significant change in N-terminal peptide abundance as compared to the wild-
type (Table 7). Even more intriguingly, six out of those seven proteins show the same 
protein quantitation when compared to the wild-type. To be more specific, two 50S 
ribosomal proteins (L2 and L17), and a third uncharacterized protein were all shown to 
have a decreased in N-terminal abundance in both the pepT1 and pepT2 mutants as 
compared to the parental strain. Furthermore, the 50S ribosomal protein L16, a 
phosphoglycerate kinase, and the Pur operon repressor proteins were only found in the 
wild-type strain, and not identified in either the pepT1 or pepT2 mutants. In addition, 
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ClpC, an ATP-dependent binding subunit protein of the Clp protease, was shown to 
have decreased abundance in the pepT2 mutant as compared to the wild-type strain, 
however was not identified in the pepT1 mutant.  
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Table 6. Wild-type and pepT2 N-Terminomics Analysis 
Identified Protein Accession # P-Value  (p <= 0.05) 
Fold  
Change  Quantitation  
Glucosamine-6-phosphate isomerase Q2FFP1_STAA3 0.023 9.24 Increase in T2 
DUF4242 superfamily; 
dipeptide/oligopeptide/nickel ABC 
transporter permease 
Q2FK91_STAA3 0.041 2.65 Increase in T2 
Cytidine deaminase Q2FGF5_STAA3 0.027 1.80 Increase in T2 
Malonyl CoA-acyl carrier protein 
transacylase  Q2FHK8_STAA3 0.0017 9.92 Decrease in T2 
50S ribosomal protein L2  RL2_STAA3 0.012 9.26 Decrease in T2 
ATP-dependent Clp protease ATP-
binding subunit ClpC  CLPC_STAA3 0.019 8.70 Decrease in T2 
DNA-directed RNA polymerase 
subunit omega  RPOZ_STAA3 0.028 6.09 Decrease in T2 
Inositol monophosphatase family 
protein  Q2FHX3_STAA3 0.0071 4.80 Decrease in T2 
50S ribosomal protein L17  RL17_STAA3 0.016 4.51 Decrease in T2 
Catabolite control protein A  Q2FG02_STAA3 0.03 4.04 Decrease in T2 
30S ribosomal protein S5 RS5_STAA3 0.035 3.30 Decrease in T2 
AANH-like and USP-like superfamily; 
universal stress protein Q2FG32_STAA3 0.0052 3.25 Decrease in T2 
Uncharacterized protein  Q2FGA2_STAA3 0.018 2.92 Decrease in T2 
Response regulator ArlR ARLR_STAA3  0.044 2.90 Decrease in T2  
30S ribosomal protein S8  RS8_STAA3 0.0085 2.54 Decrease in T2 
50S ribosomal protein L10  RL10_STAA3 0.027 1.98 Decrease in T2 
Succinyl-CoA ligase [ADP-forming] 
subunit beta  SUCC_STAA3 0.039 1.74 Decrease in T2 
50S ribosomal protein L16  RL16_STAA3 0.035 N/A Found only in WT 
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Table 6. (Continued) 	  
Heme oxygenase (staphylobilin-
producing) 2  HDOX2_STAA3 0.032 N/A Found only in WT 
Pur operon repressor  Q2FJE6_STAA3 0.0049 N/A Found only in WT 
Phosphoglycerate kinase PGK_STAA3  0.030 N/A Found only in WT 
*Listed are the proteins identified in the wild-type/pepT2 N-terminomics analysis to have 
significant changes in N-terminal peptide abundance. Strains are abbreviated as 
follows: T2 – pepT2 mutant; WT – wild-type.  A normalized T-Test of the TIC was 
performed against the total identified protein data-set with a significance level threshold 
of p <= 0.05. Quantitation profiles are indicated, representing a relative increase or 
decrease in peptide abundance as compared to the wild-type strain. 
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Table 7. Comparison of Protein Identifications 
Identified Protein Accession # pepT1 vs. WT  Quantitation  
pepT2 vs. WT  
Quantitation 
50S ribosomal protein L2  RL2_STAA3 Decreased in T1  Decreased in T2  
50S ribosomal protein L17  RL17_STAA3 Decreased in T1  Decreased in T2  
AANH-like and USP-like 
superfamily; universal stress 
protein 
Q2FG32_STAA3 Decreased in T1  Decreased in T2  
ATP-dependent Clp protease 
ATP-binding subunit ClpC  CLPC_STAA3 Only in WT Decreased in T2  
50S ribosomal protein L16  RL16_STAA3 Only in WT Only in WT 
Pur operon repressor  Q2FJE6_STAA3 Only in WT Only in WT 
Phosphoglycerate kinase PGK_STAA3  Only in WT Only in WT  
*Listed are the proteins identified in both the wild-type vs. pepT1 N-terminomics 
analysis and wild-type vs. pepT2 N-terminomics analysis to have significant changes in 
N-terminal peptide abundance. Strains are abbreviated as follows: T1 – pepT1 mutant; 
T2 – pepT2 mutant; WT – wild-type.  A normalized T-Test of the TIC was performed 
against the total identified protein data-set with a significance level threshold of p <= 
0.05. Quantitation profiles are indicated for each data-set, representing a relative 
increase or decrease in peptide abundance as compared to the wild-type strain. 
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Discussion 
 
Traditionally, bacterial aminopeptidases have been characterized for their integral role 
in protein turnover for cellular nutrition/metabolism, as well as their involvement in 
protein bioactivation/inactivation pathways; only recently has it begun to emerge that 
these enzymes can also contribute to bacterial pathogenesis (120). During a previous 
study in our lab, we revealed a S. aureus leucine aminopeptidase mutant, LAP/pepZ, to 
be attenuated in virulence in both systemic and localized models of infection (128, 130, 
132). Importantly, PepZ was the first intracellular bacterial aminopeptidase found to be 
involved in pathogenesis in Gram-positive bacteria. Although the exact molecular 
mechanisms by which PepZ functions is still unknown, it is thought that the enzyme is 
primarily responsible for the bioactivation/inactivation of key protein targets within the 
cell that are involved in the secretion of virulence factors (Carroll and Shaw, 
unpublished observation). These hypotheses are based on an intracellular and 
extracellular proteome analysis performed using the pepZ mutant, which revealed large 
alterations in protein abundance and the secretion of virulence factors as compared to 
the wild-type strain (128). Notably, a foldase, PrsA, which is known to facilitate secretion 
of virulence determinants in various Gram-positive bacteria, was significantly decreased 
in abundance in the mutant strain, suggesting that PrsA, as a substrate of PepZ, could 
mediate the avirulent phenotype observed in the pepZ mutant.  
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PepZ is part of a larger family of M17 leucine aminopeptidases, which have gained 
interest in recent years due to their involvement in virulence in Gram-negative 
organisms such as V. cholera, and P. aeruginosa (129, 133, 134). Interestingly, the M17 
aminopeptidases from both of these organisms have DNA-binding activity independent 
of their function as leucine aminopeptidases, and it is through this DNA-binding ability 
and transcriptional regulation that they affect virulence, which demonstrates the 
multifunctional properties of these enzymes. For example, the PepA enzyme in V. 
cholera is proposed to function as a DNA-binding protein, and is involved in the 
negative regulation of the ToxR regulon, which activates virulence gene expression 
(133). Disruption of the pepA gene resulted in the deregulation of pH in the pathogen, 
thus altering the expression of several virulence proteins, which are known to be 
strongly influenced by environmental and host signals (133). Furthermore, loss of the 
PhpA leucine aminopeptidase gene in P. aeruginosa resulted in an increase in algD 
transcription, which is the first gene in the alginate biosynthetic operon responsible for 
synthesizing a polysaccharide known as alginate (134). This increase in algD 
transcription mediates the switch from a nonmucoid to a highly mucoid phenotype of P. 
aeruginosa during periods of chronic cystic fibrosis infection (134). However, similar to 
the S. aureus PepZ enzyme, we do not believe the S. aureus PepT enzymes function in 
transcriptional regulation, due to the absence of any obvious DNA-binding domains or 
residues (130).   
 
Outside of the M17 family of leucine aminopeptidases, few additional bacterial 
aminopeptidases have been found to be involved in virulence. Two aminopeptidases, a 
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leucine aminopeptidase and aminopeptidase T, were found to be upregulated in the 
proteomes of virulent strains of Streptococcus suis, however their exact roles in 
pathogenesis are still undetermined (128, 172). Additionally, a pepN aminopeptidase 
mutant in S. typhimurium resulted in an increase in bacterial CFU recovery as 
compared to the wild-type from the spleen, lymph node and thymus after a 5 day 
infection period in a mouse model (173). It appears that PepN is important for restricting 
the number of bacterial CFU during later stages of systemic infection in order to 
minimize damage to the host, allowing for a successful infection that still retains a niche 
within the host (173).  
 
Because of the importance of aminopeptidases in bacterial physiology and their recently 
exposed role in pathogenesis, combined with our discovery of LAP, and its involvement 
in S. aureus disease causation, we set out to explore the role of the remaining eleven, 
non-essential, uncharacterized aminopeptidase enzymes in S. aureus, using mutants: 
pepA1, pepA2, pepA3, pepF1, pepF2, pepP1, pepP2, pepS, pepT1, pepT2, and pepV. 
During our investigations, we revealed two S. aureus aminopeptidase genes, pepT1 
and pepT2, as well as a respective pepT1/T2 double mutant, which appear to be 
important for virulence in both ex vivo models of human infection, and in vivo models of 
co-infection in mice. Importantly, the decreased fitness of the pepT mutants in whole 
human blood, coupled with the inability of these mutants to mount a systemic infection 
comparable to the parental strain, and their increased susceptibility to phagocytosis by 
host immune cells, suggest these results would be recapitulated during human infection, 
and establishes the importance of these two enzymes in S. aureus virulence. 
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Additionally, our findings mark the first aminopeptidase T enzymes to be associated 
with bacterial pathogenesis. Furthermore, no other S. aureus aminopeptidase mutants 
tested showed significant virulence defects as compared to the wild-type, with the 
exception of pepF, which showed a minor, although notable, reduction in percent 
survival in blood, suggesting the S. aureus aminopeptidase enzymes play unique roles 
among the cell, and are not all required for disease causation.  
 
Typically, aminopeptidases are known to play a role in growth and metabolism by 
liberating amino acid constituents from peptides imported into the cell, which can then 
be used in anabolic pathways (119). Additionally, these enzymes are necessary for the 
catabolism and elimination of abnormal proteins, and signal sequences derived from 
secreted proteins (119, 174, 175). Studies carried out in S. typhimurium showed 
significantly decreased degradation of intracellular peptides in mutant strains lacking 
four broad-specificity aminopeptidases: PepA, PepB, PepD, and PepN, suggesting the 
physiological necessity of these enzymes (176, 177). Similar studies were also carried 
out in E. coli, where mutant strains lacking peptidase A, B, D, N, and Q were unable to 
utilize peptides as a source of amino acids as at levels comparable to the wild-type 
strain, demonstrating that each of the five aminopeptidases function throughout growth 
and peptide utilization (178). Additionally, it has been hypothesized that the S. aureus 
PepS enzyme (AmpS) plays a crucial role in cellular growth, based on the pepS gene 
being picked up in a genome wide screen for its potential importance in cell growth 
under basic culture conditions (141). Further studies have also shown that the 
production of pepS/ampS antisense RNA, resulted in an diminished growth phenotype 
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(179). In contrast to previous studies, however, we did not detect any growth 
impairment of the pepS mutant when grown in TSB, and hypothesize the S. aureus 
PepS enzyme likely plays a role outside of cellular growth. Furthermore, in several 
Lactococcal species, aminopeptidase enzymes are necessary to allow the organism to 
exploit protein-rich environments in order to survive (156). Since these species are 
typically used for their fermentation abilities in the dairy industry, they are grown in milk, 
which contains very few nutrients, and thus rely upon their aminopeptidase activity to 
break down exogenous casein in order to supply the cell with sources of amino acids. In 
order to determine if the PepT1 and PepT2 enzymes are necessary for the degradation 
of peptides for metabolism, we assayed the ability of the pepT mutants to grow in TSB, 
a basic nutrient medium used to grow S. aureus, and 10% skim-milk to simulate a 
protein rich environment. As such, if the S. aureus PepT aminopeptidases enzymes are 
involved in cell nutrition, we would expect to see a growth defect of the aminopeptidase 
gene mutants when grown in TSB or peptide rich media. Upon observation, we saw no 
differences in growth for the pepT mutants as compared to the wild-type strain in either 
media tested, strongly indicating these enzymes are not involved in the utilization of 
peptides for growth and metabolism, as shown in S. typhimurium, E. coli, and species of 
Lactococcus. These results are similar to the previously characterized PepZ 
aminopeptidase enzyme, which also showed no growth impairment in TSB or 10% 
skim-milk (130).  
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The pepT1 and pepT2 genes are highly conserved among S. aureus isolates. BLAST 
analysis performed on the protein products of these genes indicates they are part of the 
M20 family of metallo-aminopeptidases, both of which contain six putative zinc metal 
binding site domains, indicating these enzymes likely require zinc as a metal co-factor 
for activity. According to the MEROPS peptide database, the M20 family of metallo-
peptidases is characterized by requiring two metal ions per enzyme monomer, and are 
thus of the “co-catalytic” type. Additionally, the bacterial aminopeptidase T subfamily of 
enzymes are termed tripeptidases because they are particularly known for acting upon 
tripeptide substrates. However, this is not always the case, as several homologues of 
the S. aureus PepT enzymes have been characterized, and are shown to be active 
against a variety of substrates that differ in amino acid length. Furthermore, the PepT 
homologues that have been characterized in other organisms are found to play various 
roles among the cell, and have not all been linked to nutrition. For example, a pepT 
gene mutant lacking a functional PepT enzyme in Lactococcus lactis showed no 
differences in its growth profile compared to the wild-type strain when grown in milk 
broth and casein-CDM media, indicating the enzyme is not crucial for the liberation of 
essential amino acids from casein, similar to what we see for the S. aureus PepT 
enzymes (180). Additionally, the PepT proteins from both E. coli and B. subtilis have 
been moderately characterized and were shown to possess specificity towards 
tripeptide substrates, while additional studies in E. coli have suggested a role for PepT 
in glutathione degradation (181-184). However, since S. aureus does not secrete 
glutathione, it is unlikely the PepT1 and PepT2 enzymes are involved in glutathione 
degradation. Furthermore, in the facultative intracellular pathogen S. typhimurium, the 
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PepT enzyme was found to be important in oxygen regulation, and has increased 
expression during growth under anaerobic conditions, while showing no ability to cleave 
tripeptide substrates under any of the conditions tested (185, 186). When investigating 
the role of the S. aureus pepT mutants in response to anaerobiosis, we observed no 
differences in growth as compared to the wild-type strain when exposed to anaerobic 
conditions, strongly suggesting that unlike the PepT enzyme from S. typhimurium, the 
S. aureus PepT enzymes play a role outside of oxygen regulation.  These results are 
not surprising, as S. aureus is classically considered as an extracellular pathogen, and 
is infrequently exposed to anaerobic conditions (187). Overall, the characterization of S. 
aureus PepT homologues in other organisms has proven their importance in general 
cell physiology, however, these enzymes seem to function in different cellular pathways 
than the S. aureus PepT proteins. Additionally, until this study, PepT enzymes have 
never been linked to virulence, making the S. aureus PepT1 and PepT2 proteins highly 
unique.  
 
Another characteristic of PepT1 and PepT2 is that they possess putative dimerization 
domains, suggesting these enzymes do not function as monomeric proteins. Typically, 
monomeric structures are a characteristic of secreted aminopeptidases, while the 
remaining intracellular aminopeptidases display multimeric structures (119). 
Additionally, neither the PepT1 or PepT2 proteins were predicted to possess an N-
terminal secretion signal based on SignalP analysis, strongly implying these enzymes 
are not exported, and function intracellularly. This is intriguing, as the majority of 
proteases linked to pathogenesis in S. aureus function as secreted virulence 
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determinants (104). Thus, it became important to assess the cellular localization of the 
pepT proteins, and determine if these enzymes perhaps function in a similar fashion to 
the S. aureus secreted virulence factors. Western blot analysis of S. aureus secreted, 
membrane, and cytoplasmic fractions determined both PepT1 and PepT2 to be 
intracellular enzymes throughout all stages of growth. These results suggest that unlike 
the majority of the proteases that are linked to virulence in S. aureus, the PepT 
enzymes are localized to the bacterial cytoplasm, and likely contribute to pathogenesis 
by the intracellular N-terminal processing of proteins involved in the overall maintenance 
of cellular fitness, or pathophysiological pathways.  
 
However, in order to fully understand the precise mechanisms and pathways by which 
the PepT1 and PepT2 aminopeptidase enzymes are employed in S. aureus, it is 
important to identify the exact substrate targets these proteins act upon. This was 
explored by utilizing N-terminomics; a cutting edge proteomics assay designed not only 
to identify differences in N-terminal peptide abundance, but to also gain insight into the 
slight amino acid changes associated with N-terminal processing. Through this 
approach, we identified a number of proteins with significant changes in N-terminal 
peptide abundance in the pepT1 and pepT2 mutants as compared to the wild-type 
strain. Remarkably, several of these proteins were identified in both the pepT mutant 
strains, and had similar quantitation profiles. Most notable is an overall decrease in N-
terminal peptides of ribosomal, and ribosome associated proteins in both the pepT 
mutant strain proteomes. This severe decrease in ribosomal proteins likely implies the 
cell is trying to cope with cellular stress and nutrient-limiting conditions by inducing the 
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stringent response, which dramatically downregulates translation machinery, while 
upregulating amino acid biosynthetic processes in order to increase cellular 
concentrations of free amino acids (188). The fact that the pepT mutant cells are 
inducing a stringent response indicates that the lack of PepT enzymes is causing 
significant stress on the cell, leading to a decrease in transcription of ribosomal proteins. 
Although many ribosomal proteins are essential for proper translation and overall 
function of the ribosome complex as a whole, several of these proteins are dispensable, 
and act primarily to improve ribosome stabilization (189). In a previous study aimed at 
characterizing the prokaryotic ribosome, a majority of E. coli mutants lacking such 
ribosomal proteins were still viable, and displayed no growth impairments as a result of 
the loss (190). This could explain why the severe decrease in ribosomal protein 
abundance does not affect the overall growth profiles of the pepT mutants.  
 
Additionally, a universal stress protein was identified to have significantly diminished N-
terminal abundance in both of the pepT mutants as compared to the wild-type strain. 
Though the S. aureus universal stress proteins have not been well characterized to 
date, a study analyzing the abscess proteomes from a S. aureus infection revealed a 
universal stress protein, Usp2, to be enriched in kidney lesions in mice, and involved in 
stringent stress response (191). In bacteria, transcriptional regulation of stress response 
proteins is controlled, in part, by proteases (192). Therefore, it is reasonable to 
speculate a potential role of the PepT aminopeptidases as being key regulators in a 
stress response pathway.  
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Of special interest, an ATP-dependent protease enzyme also known to be involved in 
stress response in S. aureus, ClpC, was revealed to have drastic decreases in N-
terminal peptide abundance in the pepT2 mutant as compared to the parental strain, 
and was not present at all in the pepT1 mutant N-terminomic analysis. Specifically, 
ClpC is a component of the ClpP proteolytic chamber, a barrel shaped structure 
designed to cleave unfolded protein substrates, and is widely conserved among 
bacteria (193). The role for the Clp proteases in S. aureus stress response is directed at 
the degradation of non-native and unfolded proteins which have accumulated as a 
result of dramatic changes in cellular conditions such as DNA damage, oxidative stress, 
heightened temperatures, or the presence of antimicrobial peptides (193, 194). 
Importantly, ClpP is considered to be the primary mechanism by which protein 
degradation occurs in S. aureus, and largely depends on the presence of the ClpC 
subunit for adequate function. In order for the protein substrate to enter the proteolytic 
chamber, it must first come in contact with the ClpC ATP-ase component, which is 
responsible for unfolding and translocation of the protein substrate into the active site 
(195). S. aureus strains containing a deletion of the clpP gene secreted substantially 
less extracellular enzymes and toxins, and resulted in severe attenuation of virulence, 
while additional studies demonstrated that deletion of clpC affected the transcription of 
several genes known to be involved in virulence (196-198). Additionally, in the S. 
aureus strain Newman, ClpC was found to stimulate capsule formation by dampening 
the expression of codY, which is postulated to be a mechanism conserved throughout 
all strains (197, 199). Interestingly, CodY regulates metabolism and virulence gene 
expression in S. aureus in response to nutrient availability by repressing the 
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transcription of agr (200). Furthermore, a recent study revealed AgrA, which affects 
expression of RNAIII, the effector molecule in Agr quorum-sensing, to be a direct 
substrate target of ClpC, suggesting that ClpC plays a direct role in the regulation of 
virulence in S. aureus (201). Therefore, due to the substantial role of the Clp proteases 
in S. aureus virulence, the decreased abundance of N-terminal ClpC peptides in the 
intracellular proteomes of the pepT mutants could certainly explain the avirulent 
phenotype associated with these mutants, and suggests ClpC as a potential indirect 
target of the PepT aminopeptidase enzymes.  
 
In addition to the proteins with significant changes in N-terminal abundance found in 
both pepT mutants, there were a few additional proteins of interest that were unique to 
either the pepT1 or pepT2 single mutants. Specifically, a dramatic reduction of the 
chaperone protein, DnaK was found in the pepT1 mutant. Previous studies in S. aureus 
have shown a disruption in the dnaK gene to cause a considerably reduced ability of the 
organism to survive and cause systemic infection in a mouse model, and also prove the 
importance of the DnaK enzyme in stress response (202). The DnaK enzyme is 
classified as a heat shock protein conserved throughout all organisms, which functions 
to help deal with mis-folded and aggregated proteins that have accumulated as a result 
of cellular stress, in a very similar manner as the Clp proteins (202, 203). In E. coli, 
DnaK is even believed to interact with ClpB, another member of the Clp protease family, 
in order to mediate the solubilization of proteins destined for ClpP processing (188). 
Therefore, we speculate that the decreased abundance of N-terminal peptides from 
DnaK can be attributed to the absence of the PepT1 enzyme, which likely plays a role, 
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and potentially functions as a key regulator, in S. aureus stress response pathways, 
which DnaK is also known to be intimately involved in. In the pepT2 mutant, we 
discovered a significantly decreased abundance of ArlR, the response regulator of the 
ArlRS two-component system, which is an important regulator of agglutination and 
virulence in S. aureus (204). It was found that ArlRS is responsible for controlling 
agglutination in S. aureus by modifying the expression of the ebh gene encoding the 
Giant Staphylococcal Surface Protein, GSSP.  Previous studies using an arlRS deficient 
strain of S. aureus, reveled a severe inability of the mutant strain to cause disease in 
both a sepsis and endocarditis infection model in rabbits, which can be in part 
contributed to by the decreased agglutination of the arlRS mutant strain (204). Our 
results indicate a potential interaction of the PepT2 enzyme in the ArlRS regulation 
pathways of virulence and pathogenesis in S. aureus, and could explain the virulence 
phenotypes we are seeing with the pepT2 mutant strain.  
 
S. aureus is an opportunistic pathogen, which is highly prevalent among humans, and is 
the leading cause of skin and soft tissue infections, while also causing a plethora of 
severe diseases, such as endocarditis, toxic shock syndrome, pneumonia, and 
osteomyelitis (20, 21). The extended pathogenicity of S. aureus is largely the result of 
its repertoire of virulence factors, which allow the bacterium to invade, adhere to, and 
disseminate throughout host tissues and the bloodstream. Virulence determinants of S. 
aureus include various secreted toxins, hemolysins, nucleases, proteases, and 
adhesins (67). In this study, we identified two M20 family metallo-aminopeptidases, 
PepT1 and PepT2, necessary for full S. aureus pathogenesis, which don’t seem to play 
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a major role in nutrition and metabolism. Our results demonstrate a decreased fitness of 
the pepT mutant strains in both ex vivo human, and in vivo animal models of infection, 
suggesting the lack of these enzymes causes severe cellular stress. Analysis of several 
proteins identified with altered N-terminal peptide abundance, which are potentially 
direct targets of PepT1 and PepT2, indicate these enzymes are likely involved overall 
bacterial stress response and virulence, and function through the 
bioactivation/inactivation of secondary proteins, which are tightly involved in these 
stress response, and virulence pathways.  
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Future Directions 
 
In order to elucidate further the exact roles of the S. aureus PepT1 and PepT2 
enzymes, it would be advantageous to explore the specific interactions these enzymes 
have with the proteins that were identified during the N-terminomics experiment to have 
significant changes in N-terminal peptide abundance. Due to the abundance of proteins 
identified in virulence and cellular stress response, there is a large potential that these 
enzymes function in the bioactivation or inactivation of key proteins involved in these 
pathways. In order to correlate the changes in N-terminal peptide abundance seen to 
changes in intracellular protein abundance, it would be beneficial to perform iTRAQ 
analysis on the pepT mutants. Of special interest, we aim to explore the specific role of 
the PepT enzymes in relation to the ClpC ATP-ase by creating a pepT1/pepT2/clpC 
triple mutant, followed by subsequent phenotypic analysis, in order to determine the 
overall cellular effect of the loss of all three enzymes. These results could potentially 
give insight into the cooperation of the PepT enzymes with the ClpC proteases during S. 
aureus infection and stress response. Additionally exploring the amino acid preference 
and specificity of the PepT enzymes will help to identify other potential substrate targets 
within the cell, since it has previously been shown that these enzymes can have 
functions independent of their aminopeptidase activity. 
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The PepT1 and PepT2 Enzyme Mutants Are Not Essential for Growth in Amino 
Acid Limiting Media.  
 
 
Figure A-1. The PepT1 and PepT2 Enzyme Mutants Are Not Essential for Growth 
in Amino Acid Limiting Media. Exponentially growing wild-type, pepT1 and pepT2 
mutant strains were separately inoculated, in triplicate, in CDM, an amino acid limiting 
media. Cultures were allowed to grow for 7 days. Samples were taken daily, serially 
diluted, and plated on TSA. Shown above are two independent experiments (A, B). 
Percent survival was determined by calculating CFU/mL compared to the inoculum. No 
bacteria were recovered after 4 days at 37o C with shaking. Error bars are shown ±SEM.  
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Figure A-2. The pepT1 and pepT2 Mutants Do Not Display Altered Membrane 
Integrity . Exponentially growing wild-type, pepT1 and pepT2 mutant strains were 
exposed, in triplicate, to the addition of 1.5% toluene (A), and 0.01% oleic acid (B), and 
allowed to grow for 1 h at 37oC with shaking. Samples were taken every 15 minutes, 
serially diluted, and plated in duplicate on TSA. Percent survival was determined by 
calculating CFU/mL compared to the inoculum. Error bars are shown ±SEM.  
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Figure A-3. Assaying pepT1/T2 in Response to Autolysis. Exponentially growing 
cultures of wild-type and pepT1/T2 strains were standardized to an OD600 of 0.5, and 
allowed to reach an OD600 of 1.5. Cells were then pelleted, washed three times with 
sterile PBS buffer, and re-suspended in sterile PBS buffer containing 1.5% Triton X-100. 
Cultures were incubated at 37oC with shaking, and the ODs measured every 20 min for 
a total of 140 min, with a final measurement at 24 h. Experiment was performed in 
triplicate, and ODs measured in duplicate. Percent survival was determined by the 
OD600 of each time point as compared to the initial OD600 measurement. Significance 
was determined using a student’s t-test ( * ,p < 0.05), error bars are shown ±SEM.  
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Figure A-4. Response of the pepT Mutants to Anaerobiosis. Exponentially growing 
wild-type, pepT1, pepT2, and pepT1/T2 double mutant strains were separately 
inoculated, in triplicate, in TSB. Cultures were grown anaerobically for 24 h at 37oC with 
shaking (A), as well as 37oC statically (B). Samples were taken at 0 h, 3 h, 6 h, 9 h, and 
24 h, serially diluted, and plated on TSA. Percent survival was determined by 
calculating CFU/mL compared to the inoculum. Error bars are shown ±SEM.  
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Table A-1.  Proteins Identified From N-Terminomics Analysis 
# Identified Proteins (349) Accession # Mol. 
Weight 
1 Pur operon repressor   Q2FJE6_STAA3 30 kDa 
2 50S ribosomal protein L2  RL2_STAA3 30 kDa 
3 ATP-dependent Clp protease ATP-binding subunit ClpC  CLPC_STAA3 91 kDa 
4 AANH-like and USP-like superfamily; universal stress protein Q2FG32_STAA3 15 kDa 
5 50S ribosomal protein L17  RL17_STAA3 14 kDa 
6 Dihydrofolate reductase  Q2FH12_STAA3 18 kDa 
7 50S ribosomal protein L16  RL16_STAA3 16 kDa 
8 Bifunctional purine biosynthesis protein PurH  PUR9_STAA3 54 kDa 
9 UPF0435 protein  Y1861_STAA3 8 kDa 
10 Chaperone protein DnaK  DNAK_STAA3 66 kDa 
11 Heme oxygenase (staphylobilin-producing)  HDOX2_STAA3 13 kDa 
12 Thioredoxin  THIO_STAA3 11 kDa 
13 Phosphoglycerate kinase  PGK_STAA3 43 kDa 
14 Malonyl CoA-acyl carrier protein transacylase  Q2FHK8_STAA3 34 kDa 
15 50S ribosomal protein L5  RL5_STAA3 20 kDa 
16 Response regulator ArlR  ARLR_STAA3 25 kDa 
17 Inositol monophosphatase family protein  Q2FHX3_STAA3 30 kDa 
18 Probable glycine dehydrogenase (decarboxylating) subunit 2  GCSPB_STAA3 55 kDa 
19 50S ribosomal protein L6  RL6_STAA3 20 kDa 
20 Phosphate acetyltransferase  Q2FJ55_STAA3 35 kDa 
21 Phi77 ORF011-like protein, phage transcriptional repressor  Q2FFA8_STAA3 27 kDa 
22 Cytidine deaminase  Q2FGF5_STAA3 15 kDa 
23 HTH-type transcriptional regulator SarR  SARR_STAA3 14 kDa 
24 50S ribosomal protein L22  RL22_STAA3 13 kDa 
25 Putative pyridoxal phosphate-dependent acyltransferase Q2FJ90_STAA3 43 kDa 
26 Polyribonucleotide nucleotidyltransferase  Q2FJD3_STAA3 15 kDa 
27 30S ribosomal protein S5  RS5_STAA3 18 kDa 
28 Glycerol kinase  GLPK_STAA3 56 kDa 
29 Uncharacterized protein Q2FHC5_STAA3 10 kDa 
30 Phosphoribosylformylglycinamidine synthase Q2FI11_STAA3 10 kDa 
31 Ribose-phosphate pyrophosphokinase Q2FJE1_STAA3 35 kDa 
32 Glycine betaine aldehyde dehydrogenase Q2FDP8_STAA3 55 kDa 
33 ATP-dependent zinc metalloprotease FtsH  Q2FJD0_STAA3 78 kDa 
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34 30S ribosomal protein S7  RS7_STAA3 18 kDa 
35 50S ribosomal protein L11  RL11_STAA3 15 kDa 
36 Hydroxymethylglutaryl-CoA reductase Q2FDW1_STAA3 46 kDa 
37 50S ribosomal protein L10 RL10_STAA3 18 kDa 
38 30S ribosomal protein S1 Q2FGW6_STAA3 43 kDa 
39 Glucosamine-6-phosphate isomerase Q2FFP1_STAA3 22 kDa 
40 30S ribosomal protein S3  RS3_STAA3 24 kDa 
41 Thioredoxin reductase  Q2FIM9_STAA3 34 kDa 
42 Alanine dehydrogenase  DHA1_STAA3 40 kDa 
43 Purine nucleoside phosphorylase DeoD-type Q2FEZ1_STAA3 26 kDa 
44 Probable malate:quinone oxidoreductase  Q2FDQ3_STAA3 56 kDa 
45 Glycine betaine/carnitine/choline ABC transporter  Q2FE52_STAA3 35 kDa 
46 Uncharacterized protein Q2FFL3_STAA3 10 kDa 
47 D-isomer specific 2-hydroxyacid dehydrogenase family protein Q2FFN3_STAA3 36 kDa 
48 Uncharacterized protein  Q2FGA2_STAA3 6 kDa 
49 Transferrin receptor  Q2FIQ4_STAA3 38 kDa 
50 Uncharacterized protein  Q2FIV7_STAA3 27 kDa 
51 50S ribosomal protein L27  RL27_STAA3 10 kDa 
52 30S ribosomal protein S8  RS8_STAA3 15 kDa 
53 Putative serine protease HtrA  Q2FG10_STAA3 46 kDa 
54 50S ribosomal protein L13  RL13_STAA3 16 kDa 
55 Regulatory protein Spx  Q2FI80_STAA3 15 kDa 
56 Uncharacterized protein Q2FEU8_STAA3 21 kDa 
57 30S ribosomal protein S11 RS11_STAA3 14 kDa 
58 Alcohol dehydrogenase  ADH_STAA3 36 kDa 
59 30S ribosomal protein S20 RS20_STAA3 9 kDa 
60 Dihydroorotase  Q2FHN7_STAA3 46 kDa 
61 NADH dehydrogenase-like protein  Y844_STAA3 44 kDa 
62 Elongation factor G EFG_STAA3 77 kDa 
63 Glyceraldehyde-3-phosphate dehydrogenase, type I Q2FIM1_STAA3 36 kDa 
64 50S ribosomal protein L15  RL15_STAA3 16 kDa 
65 Methionine aminopeptidase  Q2FFK7_STAA3 28 kDa 
66 Catabolite control protein A Q2FG02_STAA3 36 kDa 
67 D-isomer specific 2-hydroxyacid dehydrogenase Q2FIE4_STAA3 35 kDa 
68 Uncharacterized protein Q2FE90_STAA3 9 kDa 
69 DNA-directed RNA polymerase subunit beta  RPOB_STAA3 133kDa 
70 Uncharacterized protein  Q2FJM9_STAA3 15 kDa 
71 30S ribosomal protein S13 RS13_STAA3 14 kDa 
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72 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase GPMA_STAA3 27 kDa 
73 Staphylococcal respiratory response protein, SrrA  Q2FGP0_STAA3 28 kDa 
74 Peptidase T  PEPT_STAA3 46 kDa 
75 Glutamine—fructose-6-phosphate aminotransferase  Q2FEX8_STAA3 66 kDa 
76 Uncharacterized hydrolase Y2518_STAA3 31 kDa 
77 2-C-methyl-D-erythritol 4-phosphate cytidylyltransferase  ISPD_STAA3 27 kDa 
78 Elongation factor P  EFP_STAA3 21 kDa 
79 Putative endoribonuclease L-PSP  Q2FJE5_STAA3 14 kDa 
80 UPF0291 protein Q2FH93_STAA3 9 kDa 
81 Uncharacterized protein Q2FH59_STAA3 18 kDa 
82 Fructose-bisphosphate aldolase class 1  ALF1_STAA3 33 kDa 
83 Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit C GATC_STAA3 11 kDa 
84 Uncharacterized protein  Q2FGH7_STAA3 12 kDa 
85 HPr kinase/phosphorylase HPRK_STAA3 34 kDa 
86 Uncharacterized protein Q2FH08_STAA3 9 kDa 
87 Low molecular weight protein-tyrosine-phosphatase PtpA  PTPA_STAA3 17 kDa 
88 Uncharacterized protein  Q2FFL9_STAA3 6 kDa 
89 Putative tRNA (cytidine(34)-2’-O)-methyltransferase Q2FFP0_STAA3 18 kDa 
90 DUF4242 superfamily;  
dipeptide/oligopeptide/nickel ABC transporter permease 
Q2FK91_STAA3 19 kDa 
91 Glyoxalase family protein  Q2FGM4_STAA3 14 kDa 
92 Transcription elongation factor GreA  GREA_STAA3 18 kDa 
93 Uncharacterized protein  Q2FJN1_STAA3 36 kDa 
94 Oxidoreductase, short chain dehydrogenase/reductase family  Q2FEG8_STAA3 32 kDa 
95 ATP synthase subunit alpha ATPA_STAA3 55 kDa 
96 Glycine—tRNA ligase  SYG_STAA3 54 kDa 
97 50S ribosomal protein L32 RL32_STAA3 6 kDa 
98 Formate acetyltransferase  PFLB_STAA3 85 kDa 
99 Uncharacterized protein  Q2FFY6_STAA3 16 kDa 
100 50S ribosomal protein L7/L12  RL7_STAA3 13 kDa 
101 50S ribosomal protein L30  RL30_STAA3 7 kDa 
102 Universal stress protein family Q2FKJ2_STAA3 17 kDa 
103 Cysteine—tRNA ligase  SYC_STAA3 54 kDa 
104 Transcriptional regulator MraZ  MRAZ_STAA3 17 kDa 
105 Peptide deformylase  Q2FHY9_STAA3 21 kDa 
106 Single-stranded DNA-binding protein Q2FJP7_STAA3 19 kDa 
107 Uncharacterized protein Y736_STAA3 22 kDa 
108 Protein GrpE  GRPE_STAA3 24 kDa 	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109 Uncharacterized protein  Q2FFG7_STAA3 22 kDa 
110 Urease accessory protein UreG  UREG_STAA3 22 kDa 
111 Glutamine amidotransferase subunit PdxT  PDXT_STAA3 21 kDa 
112 Proline—tRNA ligase  SYP_STAA3 64 kDa 
113 6,7-dimethyl-8-ribityllumazine synthase  RISB_STAA3 16 kDa 
114 Glyceraldehyde-3-phosphate dehydrogenase, type I  Q2FG50_STAA3 37 kDa 
115 Nucleoside diphosphate kinase  NDK_STAA3 17 kDa 
116 50S ribosomal protein L19  RL19_STAA3 13 kDa 
117 3-hexulose-6-phosphate synthase  HPS_STAA3 22 kDa 
118 Acetyltransferase, GNAT family Q2FEZ9_STAA3 33 kDa 
119 Putative formate dehydrogenase FDHL_STAA3 111 kDa 
120 Clumping factor A  Q2FIK6_STAA3 97 kDa 
121 Glutamate racemase MURI_STAA3 30 kDa 
122 Translation initiation factor IF-2  IF2_STAA3 78 kDa 
123 Uncharacterized protein  Q2FG26_STAA3 36 kDa 
124 Uncharacterized protein Q2FII5_STAA3 34 kDa 
125 DNA-directed RNA polymerase subunit beta’  RPOC_STAA3 135 kDa 
126 ATP-dependent DNA helicase, PcrA  Q2FFJ0_STAA3 84 kDa 
127 Penicillin-binding protein 1 Q2FHQ6_STAA3 83 kDa 
128 Uncharacterized protein  Q2FDR5_STAA3 17 kDa 
129 Uncharacterized protein Q2FIW1_STAA3 11 kDa 
130 Molecular chaperone Hsp31 and 144lyoxalase 3 HCHA_STAA3 32 kDa 
131 UPF0365 protein Y1533_STAA3 35 kDa 
132 Peptide methionine sulfoxide reductase MsrA  Q2FH14_STAA3 21 kDa 
133 Uncharacterized protein  Q2FGY0_STAA3 25 kDa 
134 Anti-sigma factor antagonist  Q2FF58_STAA3 12 kDa 
135 Hydrolase, TatD family  Q2FJF1_STAA3 29 kDa 
136 Protein ArsC  ARSC_STAA3 15 kDa 
137 N utilization substance protein B homolog  NUSB_STAA3 15 kDa 
138 NH(3)-dependent NAD(+) synthetase NADE_STAA3 31 kDa 
139 Putative pyruvate, phosphate dikinase regulatory protein PDRP_STAA3 31 kDa 
140 RNA methyltransferase, TrmH family, group 3  Q2FJA8_STAA3 27 kDa 
141 Transaldolase  Q2FFW0_STAA3 26 kDa 
142 Antibacterial protein Q2FHR4_STAA3 4 kDa 
143 Uncharacterized protein  Q2FHZ8_STAA3 20 kDa 
144 Putative glycerophosphoryl diester phosphodiesterase  Q2FKM8_STAA3 28 kDa 
145 Threonine—tRNA ligase  SYT_STAA3 74 kDa 
146 Protein translocase subunit SecA 1  SECA1_STAA3 96 kDa 
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147 Uncharacterized protein  Q2FGJ4_STAA3 12 kDa 
148 30S ribosomal protein S14 type Z  RS14Z_STAA3 7 kDa 
149 Uncharacterized protein  Q2FDS2_STAA3 12 kDa 
150 Xanthine phosphoribosyltransferase  XPT_STAA3 21 kDa 
151 Molybdenum cofactor biosynthesis protein B  Q2FEL7_STAA3 18 kDa 
152 Uncharacterized protein  Q2FGY1_STAA3 12 kDa 
153 ATP-dependent protease ATPase subunit HslU  HSLU_STAA3 52 kDa 
154 Serine-protein kinase RsbW  RSBW_STAA3 18 kDa 
155 Pyruvate dehydrogenase E1 component, beta subunit  Q2FHY6_STAA3 35 kDa 
156 Uncharacterized protein Q2FFM0_STAA3 19 kDa 
157 Putative 2-hydroxyacid dehydrogenase Y2254_STAA3 35 kDa 
158 Probable endonuclease 4  END4_STAA3 33 kDa 
159 CON__P08779 CON__P08779 ? 
160 Glutamyl-aminopeptidase  Q2FE43_STAA3 39 kDa 
161 Uncharacterized protein  Q2FF40_STAA3 8 kDa 
162 50S ribosomal protein L29  Q2FEP7_STAA3 9 kDa 
163 Veg protein  Q2FJE8_STAA3 10 kDa 
164 Succinyl-CoA ligase [ADP-forming] subunit beta  SUCC_STAA3 42 kDa 
165 DNA-binding protein HU  Q2FGW9_STAA3 10 kDa 
166 Translation initiation factor IF-1  IF1_STAA3 8 kDa 
167 Lysine—tRNA ligase  SYK_STAA3 57 kDa 
168 Mannitol-1-phosphate 5-dehydrogenase  MTLD_STAA3 41 kDa 
169 Phosphoenolpyruvate-protein phosphotransferase  Q2FHZ6_STAA3 63 kDa 
170 Mannose-6-phosphate isomerase, class I  Q2FDL7_STAA3 35 kDa 
171 UPF0337 protein  Y816_STAA3 7 kDa 
172 Phosphoglucosamine mutase  GLMM_STAA3 49 kDa 
173 DNA-directed RNA polymerase subunit omega RPOZ_STAA3 8 kDa 
174 Alcohol dehydrogenase, zinc-containing  Q2FK14_STAA3 38 kDa 
175 UPF0457 protein  Y2132_STAA3 10 kDa 
176 Galactose-6-phosphate isomerase subunit LacA  LACA_STAA3 15 kDa 
177 S-ribosylhomocysteine lyase LUXS_STAA3 18 kDa 
178 Dihydrolipoyl dehydrogenase  Q2FHY4_STAA3 49 kDa 
179 Uncharacterized protein Q2FE41_STAA3 10 kDa 
180 PTS system EIIBC component  PTXBC_STAA3 51 kDa 
181 DNA topoisomerase 4 subunit A Q2FH80_STAA3 91 kDa 
182 HIT family protein  Q2FFQ8_STAA3 16 kDa 
183 Dihydroxyacetone kinase, DhaL subunit  Q2FIY8_STAA3 21 kDa 
184 Alkyl hydroperoxide reductase subunit C  AHPC_STAA3 21 kDa 
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185 Acetyl-CoA carboxylase, biotin carboxyl carrier protein Q2FGB9_STAA3 17 kDa 
186 Phenol-soluble modulin alpha 4 peptide PSMA4_STAA3 2 kDa 
187 Triosephosphate isomerase  TPIS_STAA3 27 kDa 
188 Transcription termination factor NusA  Q2FHH2_STAA3 44 kDa 
189 Uncharacterized protein Q2FK92_STAA3 8 kDa 
190 Uncharacterized protein  Q2FKN1_STAA3 49 kDa 
191 Uncharacterized protein  Q2FEB6_STAA3 16 kDa 
192 Transcription termination/antitermination protein NusG  Q2FJA4_STAA3 21 kDa 
193 Branched-chain-amino-acid aminotransferase  Q2FJ86_STAA3 40 kDa 
194 Putative NADP-dependent malic enzyme  Q2FG36_STAA3 44 kDa 
195 Potassium uptake protein  Q2FHZ2_STAA3 24 kDa 
196 Uncharacterized protein  Q2FID7_STAA3 39 kDa 
197 Probable DNA-directed RNA polymerase subunit delta  RPOE_STAA3 21 kDa 
198 30S ribosomal protein S4  RS4_STAA3 23 kDa 
199 Uncharacterized protein  Q2FI49_STAA3 7 kDa 
200 Citrate synthase Q2FG42_STAA3 43 kDa 
201 30S ribosomal protein S16  RS16_STAA3 10 kDa 
202 Aspartate-semialdehyde dehydrogenase1 Q2FH44_STAA3 36 kDa 
203 30S ribosomal protein S18  RS18_STAA3 9 kDa 
204 Tyrosine—tRNA ligase SYY_STAA3 48 kDa 
205 Uncharacterized protein  Q2FEN1_STAA3 6 kDa 
206 Putative cell-division initiation protein  Q2FHP5_STAA3 24 kDa 
207 30S ribosomal protein S6  RS6_STAA3 12 kDa 
208 Uknown_Protein_13398 ? ? 
209 Rhodanese-like domain protein Q2FFY1_STAA3 11 kDa 
210 Succinyl-CoA ligase [ADP-forming] subunit alpha  Q2FHJ2_STAA3 32 kDa 
211 D-alanine—poly(phosphoribitol) ligase subunit 1 DLTA_STAA3 55 kDa 
212 Putative thioredoxin  Q2FII9_STAA3 12 kDa 
213 Probable thiol peroxidase  Q2FG25_STAA3 18 kDa 
214 60 kDa chaperonin CH60_STAA3 58 kDa 
215 50S ribosomal protein L31 type B  RL31B_STAA3 10 kDa 
216 50S ribosomal protein L14  RL14_STAA3 13 kDa 
217 Putative sporulation transcription regulator WhiA  WHIA_STAA3 36 kDa 
218 GTP cyclohydrolase FolE2  GCH4_STAA3 33 kDa 
219 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-acetyltransferase DAPH_STAA3 25 kDa 
220 30S ribosomal protein S2  RS2_STAA3 29 kDa 
221 Phenol-soluble modulin alpha 1 peptide PSMA1_STAA3 2 kDa 
222 Serine—tRNA ligase  SYS_STAA3 49 kDa 
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223 Uracil phosphoribosyltransferase  UPP_STAA3 23 kDa 
224 Methylenetetrahydrofolate—tRNA-(uracil-5-)-methyltransferase TrmFO TRMFO_STAA3 48 kDa 
225 Phosphoribosylaminoimidazole-succinocarboxamide synthase PUR7_STAA3 27 kDa 
226 UPF0477 protein Y916_STAA3 19 kDa 
227 Uncharacterized protein  Q2FFQ7_STAA3 13 kDa 
228 Dihydrolipoamide acetyltransferase Q2FHY5_STAA3 46 kDa 
229 50S ribosomal protein L4  RL4_STAA3 22 kDa 
230 Putative septation protein SpoVG  SP5G_STAA3 11 kDa 
231 Fructose bisphosphate aldolase  Q2FF03_STAA3 31 kDa 
232 NADH-dependent FMN reductase  Q2FJS4_STAA3 21 kDa 
233 50S ribosomal protein L23  RL23_STAA3 11 kDa 
234 UPF0741 protein  Y575_STAA3 14 kDa 
235 Phosphoribosylformylglycinamidine synthase 2  PURL_STAA3 80 kDa 
236 50S ribosomal protein L28 RL28_STAA3 7 kDa 
237 DNA polymerase III subunit beta  Q2FKQ4_STAA3 42 kDa 
238 50S ribosomal protein L25  RL25_STAA3 24 kDa 
239 UPF0403 protein  Y1321_STAA3 16 kDa 
240 Copper chaperone CopZ  COPZ_STAA3 7 kDa 
241 Probable uridylyltransferase URTF_STAA3 45 kDa 
242 Delta-hemolysin  Q2FF89_STAA3 5 kDa 
243 Ornithine aminotransferase  Q2FIB8_STAA3 43 kDa 
244 Putative acyl-CoA acetyltransferase FadA  Q2FK39_STAA3 42 kDa 
245 UPF0122 protein Y1129_STAA3 14 kDa 
246 Cell cycle protein GpsB  GPSB_STAA3 13 kDa 
247 UPF0342 protein  Y1795_STAA3 13 kDa 
248 Putative oxidoreductase  Q2FJT5_STAA3 38 kDa 
249 Imidazolonepropionase HUTI_STAA3 45 kDa 
250 Guanylate kinase  KGUA_STAA3 24 kDa 
251 30S ribosomal protein S15  RS15_STAA3 11 kDa 
252 Elongation factor Tu EFTU_STAA3 43 kDa 
253 MutT/nudix family protein  Q2FG59_STAA3 23 kDa 
254 GTP-sensing transcriptional pleiotropic repressor CodY CODY_STAA3 29 kDa 
255 Putative dipeptidase  PEPVL_STAA3 53 kDa 
256 30S ribosomal protein S10  RS10_STAA3 12 kDa 
257 Serine hydroxymethyltransferase GLYA_STAA3 45 kDa 
258 1-pyrroline-5-carboxylate dehydrogenase  ROCA_STAA3 57 kDa 
259 MutT/nudix family protein Q2FGN3_STAA3 20 kDa 
260 Methylated DNA-protein cysteine methyltransferase Q2FDV9_STAA3 19 kDa 
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261 Putative peptidyl-prolyl cis-trans isomerase  PPI1_STAA3 22 kDa 
262 L-lactate dehydrogenase 1 LDH1_STAA3 35 kDa 
263 Uncharacterized protein  Q2FJF9_STAA3 12 kDa 
264 Putative lipoprotein  Q2FJP2_STAA3 21 kDa 
265 50S ribosomal protein L35  RL35_STAA3 8 kDa 
266 Uncharacterized protein  Q2FG19_STAA3 17 kDa 
267 Putative thioredoxin Q2FFZ4_STAA3 12 kDa 
268 Thymidylate kinase  KTHY_STAA3 23 kDa 
269 Hydroxymethylglutaryl-CoA synthase Q2FDW0_STAA3 43 kDa 
270 Putative NAD(P)H nitroreductase Y2462_STAA3 25 kDa 
271 50S ribosomal protein L21  RL21_STAA3 11 kDa 
272 Translation initiation factor IF-3  IF3_STAA3 20 kDa 
273 Phosphocarrier protein HPr  Q2FHZ7_STAA3 9 kDa 
274 33 kDa chaperonin HSLO_STAA3 32 kDa 
275 Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha  ACCA_STAA3 35 kDa 
276 Phenylalanyl-tRNA synthetase (Beta subunit) Q2FFZ6_STAA3 22 kDa 
277 Cold shock protein CspA  CSPA_STAA3 7 kDa 
278 Acetoin(Diacetyl) reductase  Q2FKD2_STAA3 27 kDa 
279 Nitroreductase family protein  Q2FIJ0_STAA3 21 kDa 
280 4-oxalocrotonate tautomerase  Q2FH73_STAA3 7 kDa 
281 30S ribosomal protein S19  RS19_STAA3 11 kDa 
282 Uncharacterized protein  Q2FID9_STAA3 9 kDa 
283 Probable manganese-dependent inorganic pyrophosphatase  PPAC_STAA3 34 kDa 
284 Superoxide dismutase [Mn/Fe] 2  SODM2_STAA3 23 kDa 
285 30S ribosomal protein S9  RS9_STAA3 15 kDa 
286 SUF system FeS assembly protein, NifU family Q2FIF7_STAA3 17 kDa 
287 Organic hydroperoxide resistance protein-like  OHRL_STAA3 15 kDa 
288 Elastin-binding protein EbpS EBPS_STAA3 53 kDa 
289 Acyl carrier protein  ACP_STAA3 9 kDa 
290 Ribosome-binding ATPase YchF  Q2FJQ0_STAA3 41 kDa 
291 D-alanine—poly(phosphoribitol) ligase subunit 2  DLTC_STAA3 9 kDa 
292 2,3-bisphosphoglycerate-independent phosphoglycerate mutase Q2FIL8_STAA3 56 kDa 
293 D-lactate dehydrogenase Q2FDY1_STAA3 39 kDa 
294 Uncharacterized protein  Q2FHE7_STAA3 11 kDa 
295 Aerobic glycerol-3-phosphate dehydrogenase GLPD_STAA3 62 kDa 
296 Lantibiotic epidermin immunity protein F Q2FFS5_STAA3 26 kDa 
297 UPF0337 protein  Y1582_STAA3 7 kDa 
298 6-phosphogluconate dehydrogenase, decarboxylating  Q2FGM3_STAA3 52 kDa 
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299 Putative Holliday junction resolvase  RUVX_STAA3 16 kDa 
300 Iron-sulfur cluster repair protein ScdA  SCDA_STAA3 25 kDa 
301 Arginase Q2FEW8_STAA3 33 kDa 
302 Pyridoxal biosynthesis lyase PdxS  PDXS_STAA3 32 kDa 
303 30S ribosomal protein S12  RS12_STAA3 15 kDa 
304 Cell division protein FtsZ Q2FHQ1_STAA3 41 kDa 
305 Maltose operon transcriptional repressor Q2FGM5_STAA3 38 kDa 
306 50S ribosomal protein L18  RL18_STAA3 13 kDa 
307 10 kDa chaperonin CH10_STAA3 10 kDa 
308 Alkaline shock protein 23  ASP23_STAA3 19 kDa 
309 Trigger factor  TIG_STAA3 49 kDa 
310 2-oxoisovalerate dehydrogenase, E1 component, beta subunit  Q2FGL7_STAA3 36 kDa 
311 Inosine-5’-monophosphate dehydrogenase  IMDH_STAA3 53 kDa 
312 DNA-directed RNA polymerase subunit alpha RPOA_STAA3 35 kDa 
313 Phosphoribosylformylglycinamidine cyclo-ligase  PUR5_STAA3 37 kDa 
314 Cysteine synthase Q2FJC8_STAA3 33 kDa 
315 Putative universal stress protein Y1656_STAA3 18 kDa 
316 50S ribosomal protein L20  RL20_STAA3 14 kDa 
317 UPF0356 protein  Y990_STAA3 9 kDa 
318 Deoxyribose-phosphate aldolase  Q2FEZ2_STAA3 23 kDa 
319 50S ribosomal protein L3  RL3_STAA3 24 kDa 
320 Enolase  ENO_STAA3 47 kDa 
321 Uncharacterized protein  Q2FJY6_STAA3 11 kDa 
322 Transcriptional regulator SarA  SARA_STAA3 15 kDa 
323 Ribosome-recycling factor  RRF_STAA3 20 kDa 
324 ATP-dependent Clp protease proteolytic subunit CLPP_STAA3 22 kDa 
325 Uncharacterized protein Q2FHV4_STAA3 21 kDa 
326 3-oxoacyl-(Acyl-carrier-protein) reductase Q2FHK7_STAA3 26 kDa 
327 UDP-N-acetylglucosamine 1-carboxyvinyltransferase Q2FF04_STAA3 45 kDa 
328 ATP-dependent Clp protease ATP-binding subunit ClpL CLPL_STAA3 78 kDa 
329 Adenylate kinase Q2FER0_STAA3 24 kDa 
330 Glycine cleavage system H protein GCSH_STAA3 14 kDa 
331 50S ribosomal protein L9 RL9_STAA3 16 kDa 
332 ABC transporter, ATP-binding protein Q2FH46_STAA3 60 kDa 
333 Uncharacterized protein Q2FJP1_STAA3 11 kDa 
334 CamS sex pheromone cAM373 Q2FFJ2_STAA3 45 kDa 
335 ATP synthase subunit beta ATPB_STAA3 51 kDa 
336 Pyruvate kinase  KPYK_STAA3 63 kDa 
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337 Elongation factor Ts EFTS_STAA3 32 kDa 
338 Alkyl hydroperoxide reductase, subunit F Q2FJN5_STAA3 55 kDa 
339 Bifunctional protein FolD FOLD_STAA3 31 kDa 
340 30S ribosomal protein S21 RS21_STAA3 7 kDa 
341 Putative arsenate reductase  Q2FII8_STAA3 14 kDa 
342 Pyruvate dehydrogenase E1 component, alpha subunit Q2FHY7_STAA3 41 kDa 
343 Hydroxyethylthiazole kinase THIM_STAA3 28 kDa 
344 Nucleoid-associated protein Y453_STAA3 12 kDa 
*Listed are the HPLC-MS/MS identified proteins from the N-terminomic analysis of the 
wild-type, pepT1, and pepT2 mutant intracellular proteomes. Protein data-sets were 
validated by searching against a known S. aureus protein database.  Accession 
numbers correspond to the GenBank protein accession numbers located in the National 
Center for Biotechnology Information (NCBI). 
